☆ 4.7 Review

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Related references

Note: Only part of the references are listed.
Review Hematology

The clinical impact of the molecular landscape of acute myeloid leukemia

Sabine Kayser et al.

Summary: Research on acute myeloid leukemia (AML) has advanced our understanding of the disease, especially in cytogenetically defined subsets of AML. Despite progress in deciphering the tumor genome, only a few recurrent mutations have been incorporated into risk stratification schemes and proven to be clinically relevant. This article discusses the use of molecular markers in AML for prognosis and treatment decision-making, as well as new therapies targeting specific markers.

HAEMATOLOGICA (2023)

Add to Collection
Article Immunology

Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells

Faruk Sacirbegovic et al.

IMMUNITY (2023)

Add to Collection
Article Biochemistry & Molecular Biology

Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma

Zhuohao Liu et al.

Summary: This study validated the safety and efficacy of GD2-specific fourth-generation safety-designed chimeric antigen receptor (4SCAR)-T cells in the treatment of GD2-positive glioblastoma. Infusion of autologous GD2-specific 4SCAR-T cells was safe and well tolerated, with partial responses observed in some patients and activation of immune responses in the tumor microenvironment.

MOLECULAR CANCER (2023)

Add to Collection
Review Chemistry, Multidisciplinary

Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights

Jiao-jiao Ni et al.

Summary: As a breakthrough strategy for cancer treatment, immunotherapy stimulates the immune system to fight cancer, providing a durable antitumor response. Due to the low response rate and unique toxicity profiles of immunotherapy, combining it with other therapies has gained attention. Immune-based combination therapy has achieved promising results in clinical trials, with FDA approval for certain cancers.

ACTA PHARMACOLOGICA SINICA (2023)

Add to Collection
Article Biochemistry & Molecular Biology

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Sham Mailankody et al.

Summary: In an interim phase 1 trial analysis, escalating doses of off-the-shelf allogeneic anti-BCMA CAR T cells, in combination with an anti-CD52 antibody-containing lymphodepletion regimen, were shown to be feasible and safe for the treatment of relapsed or refractory multiple myeloma.

NATURE MEDICINE (2023)

Add to Collection
Review Oncology

Advancing CAR T cell therapy through the use of multidimensional omics data

Jingwen Yang et al.

Summary: This article provides an overview of the multidimensional profiling technologies used in CAR T cell therapy research and discusses the utilization of multi-omics data to elucidate CAR targets, factors associated with response or resistance to therapy, and underlying toxicities. These findings can potentially enhance the efficacy and safety of CAR T cell therapies.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Add to Collection
Article Oncology

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

Meletios A. Dimopoulos et al.

Summary: In the phase II ELOQUENT-3 trial, the combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd) showed significant improvement in progression-free survival (PFS) compared to Pomalidomide and Dexamethasone (Pd) in relapsed/refractory multiple myeloma patients previously treated with Lenalidomide and a proteasome inhibitor. The final overall survival (OS) results revealed that EPd had a statistically significant improvement in OS.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection
Article Hematology

Ponatinib and blinatumomab for Philadelphia chromosome- positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Elias Jabbour et al.

Summary: In this study, the researchers evaluated the combination of ponatinib and blinatumomab as a chemotherapy-free treatment strategy for Philadelphia chromosome-positive acute lymphoblastic leukaemia. The results showed that this combination therapy achieved high rates of complete molecular response in patients with newly diagnosed and relapsed or refractory disease.

LANCET HAEMATOLOGY (2023)

Add to Collection
Article Hematology

GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial

Mingming Zhang et al.

Lancet Haematology (2023)

Add to Collection
Review Oncology

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

Toan D. Nguyen et al.

Summary: Antibody-drug conjugates (ADCs) are a rapidly expanding class of anti-cancer drugs, but many fail during clinical development due to toxicities and risk-benefit issues. Even approved ADCs often lead to dose reduction or treatment discontinuation due to intolerable toxicity. This report reviews the mechanisms contributing to ADC toxicity and discusses strategies to improve tolerability.

CANCERS (2023)

Add to Collection
Review Hematology

Antibody drug conjugates for the treatment of multiple myeloma

Sarah Leong et al.

Summary: The treatment landscape of multiple myeloma has evolved, necessitating new treatment options. Antibody drug conjugates (ADCs) have emerged as a promising class for targeted therapy. However, the design of effective and tolerable ADCs remains challenging, with only one ADC currently approved for multiple myeloma treatment.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection
Review Hematology

How I treat cytopenias after CAR T-cell therapy

Tania Jain et al.

Summary: The increasing use of CAR-T therapy has led to the discovery of diverse toxicities, such as cytopenias, which require specific recognition and management. These cytopenias usually occur early after CAR-T infusion (<30 days), can be prolonged (30-90 days), and sometimes persist or happen late (>90 days). The causes of these cytopenias are variable and some are not fully understood, creating clinical challenges and uncertainties in choosing the best management strategies. These cytopenias can result in additional complications, reduced quality of life, and increased resource utilization.

BLOOD (2023)

Add to Collection
Article Hematology

How I treat refractory CRS and ICANS after CAR T-cell therapy

Michael D. Jain et al.

Summary: The clinical use of CAR T-cell therapy is expanding due to increasing indications for treatment and new investigational products. Standard diagnostic criteria for CRS and ICANS, along with the use of tocilizumab and corticosteroids, have facilitated its widespread use. Preemptive interventions have improved safety, but persistent or progressive toxicities still pose challenges.

BLOOD (2023)

Add to Collection
Review Hematology

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities

Lorenzo Falchi et al.

Summary: Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have undergone significant changes in the past two decades due to the introduction of highly active immunotherapies. Bispecific antibodies (BsAb) have emerged as a promising immunotherapeutic for B-NHL, with anti-CD20xCD3 BsAb showing remarkable single-agent activity. However, further research is needed to determine the optimal deployment of these drugs, ideal combination partners, strategies for minimizing toxicity, and pharmacodynamic biomarkers of response and resistance.

BLOOD (2023)

Add to Collection
Article Medicine, General & Internal

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodriguez-Otero et al.

Summary: In this international phase 3 trial, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, was found to significantly prolong progression-free survival and improve response compared to standard regimens in patients with relapsed and refractory multiple myeloma. The toxicity of ide-cel was consistent with previous reports.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection
Article Oncology

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

Yinqiang Zhang et al.

Summary: This study compared the differences between autologous and allogeneic anti-CD7 CAR-T therapies in T-cell malignancies and found that patients treated with allogeneic CAR-T cells had a higher remission rate, less recurrence, and more durable CAR-T survival. This suggests that allogeneic CAR-T cells are a better option for patients with T-cell malignancies.

BLOOD CANCER JOURNAL (2023)

Add to Collection
Article Hematology

Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past

Nicholas J. Short et al.

Summary: Department of Multidrug chemotherapy has historically been the cornerstone of therapy for both children and adults with acute lymphocytic leukaemia. However, in the past decade, several novel immunotherapies have proven to be highly effective in the treatment of acute lymphocytic leukaemia, including the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3 x CD19 bispecific antibody blinatumomab, and two CD19-directed chimeric antigen receptor T-cell products. These agents are all approved in the USA as monotherapy for relapsed or refractory B-cell acute lymphocytic leukaemia. However, their use as single agents in the salvage setting might not be taking full advantage of their anti-leukaemia potential, because our ability to cure a patient is likely to be greatest when the most effective therapies are safety integrated into front-line treatment regimens. Several ongoing studies have yielded encouraging data with routine incorporation of inotuzumab ozogamicin or blinatumomab, or both, in patients with newly diagnosed acute lymphocytic leukaemia, and these approaches are emerging as new standards of care. In Philadelphia chromosome-positive acute lymphocytic leukaemia, chemotherapy-free regimens combining blinatumomab and a BCR-ABL1 tyrosine kinase inhibitor are changing acute lymphocytic leukaemia therapy, highlighting the potential for these novel agents to reduce-or perhaps eliminate-the need for chemotherapy in some subtypes. In this Viewpoint, we review promising data from ongoing clinical trials of novel immunotherapy-based combinations that are being explored in patients with newly diagnosed acute lymphocytic leukaemia. We also discuss the challenges of randomised studies in the rapidly evolving therapeutic landscape and argue for the ability of well designed, non-randomised studies to more advance the standard of care in acute leukaemia.

LANCET HAEMATOLOGY (2023)

Add to Collection
Article Oncology

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL

Fengmei Song et al.

Summary: This study evaluates the safety and efficacy of humanized CD19-targeted CAR-T cell (hCART19) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The results show that 93.1% of patients achieved complete remission or remission with incomplete count recovery by day 28, with a median follow-up of 13.5 months. The 1-year overall survival and event-free survival rates were 73.6% and 46.0% respectively, with manageable toxicities.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection
Review Oncology

Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Rujul H. Parikh et al.

Summary: Multiple myeloma is a difficult-to-cure hematologic malignancy. Chimeric antigen receptor (CAR) T-cell therapy has shown promising efficacy in relapsed, refractory multiple myeloma patients, but durable responses are still a challenge. This comprehensive review discusses the development of CAR T-cell therapies, clinical trial outcomes, toxicities and limitations, and strategies to overcome therapeutic challenges, aiming for a cure for multiple myeloma.

CA-A CANCER JOURNAL FOR CLINICIANS (2023)

Add to Collection
Article Oncology

Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis

Youwen Zhu et al.

Summary: Different ADCs appear to have varying effects on treatment-related adverse events, providing comprehensive data for clinicians and patients on how to manage toxicities from ADCs in clinical practice.

CANCER (2023)

Add to Collection
Article Medicine, Research & Experimental

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Michael Boyiadzis et al.

Summary: This study aimed to identify a recommended phase II dose of JNJ-63709178 and assess its safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary clinical activity in patients with relapsed or refractory acute myeloid leukemia. The results revealed suboptimal drug exposure, unfavorable safety profiles, and limited clinical activity for both intravenous and subcutaneous administration of JNJ-63709178.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Add to Collection
Article Hematology

Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia

Ming Shi et al.

Summary: The use of humanized CD19-specific CAR-T cells (hCART19s) in treating R/R ALL patients has shown safety and high efficacy. However, the treatment may induce the development of antidrug antibodies (ADA) which are associated with disease relapse risk.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection
Article Hematology

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi et al.

Summary: Lisocabtagene maraleucel, an autologous CD19-directed CAR T-cell therapy, shows promising safety and efficacy in patients with relapsed/refractory CLL/SLL, providing a potential new treatment option for these patients who develop resistance to current therapies.

BLOOD (2022)

Add to Collection
Review Oncology

Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment

Allison M. Bock et al.

Summary: Despite challenges in treating R/R NHL, CD20 x CD3 BsAbs have shown promising efficacy with reduced toxicity. With ongoing expansion and registrational studies, approvals for R/R NHL treatment are expected soon. Further exploration is needed to determine the role of BsAbs in treatment-naive NHL and how to combine them with other therapies, as well as to compare and sequence BsAbs with CAR T-cell therapy.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

Add to Collection
Letter Hematology

A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Sumithira Vasu et al.

HAEMATOLOGICA (2022)

Add to Collection
Article Hematology

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial

Nigel H. Russell et al.

Summary: Reduced intensity conditioning (RIC) transplantation is a beneficial option for older patients with acute myeloblastic leukemia lacking favorable-risk cytogenetics.

HAEMATOLOGICA (2022)

Add to Collection
Article Oncology

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson et al.

Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.

LANCET ONCOLOGY (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Ming Yi et al.

Summary: Antibodies targeting PD-1/PD-L1 revive immune response against cancer cells, but the low response rate calls for combination therapies. Combining with chemotherapy, radiotherapy, and other treatments can achieve better outcomes, and individualized combination selection is needed to overcome treatment resistance.

MOLECULAR CANCER (2022)

Add to Collection
Article Biotechnology & Applied Microbiology

Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma

Pingyan Cheng et al.

Summary: This study found that MDSCs play an important role in the pathogenesis of MDS, and depletion of MDSCs may improve resistance to checkpoint inhibitors. Combination of AMV564 with anti-PD1 enhances the activation of cytotoxic T cells, showing potential for improving therapeutic efficacy.

MOLECULAR THERAPY (2022)

Add to Collection
Article Multidisciplinary Sciences

Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells

J. Joseph Melenhorst et al.

Summary: CAR T cells redirected to target CD19 demonstrated long-lasting potential and clonal stability in two patients with chronic lymphocytic leukaemia. Highly activated CD4(+) cells emerged and dominated the CAR T cell population at later time points. These unexpected CAR T cell populations provide novel insights into anti-cancer response and long-term remission in leukaemia.

NATURE (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Hale Fowler et al.

Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.

NATURE MEDICINE (2022)

Add to Collection
Article Medicine, General & Internal

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

M. R. Bishop et al.

Summary: Tisagenlecleucel did not demonstrate superiority over standard salvage therapy in this trial. Further studies are needed to evaluate which patients may benefit the most from each approach.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Review Oncology

Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade

Natalija Budimir et al.

Summary: Anti-PD-1/PD-L1 immune checkpoint blockade therapy has revolutionized cancer treatment, but recent studies have revealed the complexity and heterogeneity of CD8 +/- T cell populations in the tumor microenvironment. These studies have also found that CD8 +/- T cell states within and outside the tumor microenvironment have different capacities to respond to immunotherapy.

CANCER IMMUNOLOGY RESEARCH (2022)

Add to Collection
Review Allergy

Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions

Jeanette Wat et al.

Summary: Chimeric antigen receptor (CAR) T-cell therapy is a dynamic treatment for hematologic malignancies that offers long-term remissions but can have life-threatening side effects, including severe infections. B-cell aplasia is a common side effect that leads to hypogammaglobulinemia. This review discusses the occurrence, duration, and immune recovery of hypogammaglobulinemia observed in approved CAR T-cell therapies and clinical trials. It also explores the association between hypogammaglobulinemia and infections, with a focus on management strategies for evaluation and immunoglobulin replacement. The review also highlights newer CAR T-cell products targeting different B-cell antigens and identifies areas for future study to address hypogammaglobulinemia resulting from this therapy.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

Add to Collection
Article Oncology

Soluble PD-L1 as an early marker of progressive disease on nivolumab

Kathleen M. Mahoney et al.

Summary: This study investigated the levels of soluble PD-L1 (sPD-L1) before and during nivolumab treatment in metastatic clear cell renal cell carcinoma (RCC) and melanoma patients. The results showed that sPD-L1 levels were associated with worse prognosis and clinical factors. Additionally, changes in sPD-L1 levels during treatment were linked to treatment outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection
Article Hematology

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis

Nico Gagelmann et al.

Summary: This study analyzed the outcomes of reduced intensity transplantation in 349 patients with myelofibrosis, including 35 patients with accelerated-phase myelofibrosis. The results showed that the overall survival and nonrelapse mortality rates were not significantly different between the accelerated-phase and chronic-phase groups, but the accelerated-phase group had a higher incidence of relapse.

BLOOD ADVANCES (2022)

Add to Collection
Article Oncology

Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

Bryan J. Schneider et al.

JCO ONCOLOGY PRACTICE (2022)

Add to Collection
Article Hematology

Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial

Dietrich W. Beelen et al.

Summary: In older or comorbid patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation, treosulfan-based conditioning regimen shows better event-free survival and overall survival compared to a widely applied reduced-intensity conditioning busulfan regimen.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection
Article Oncology

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

S. Horwitz et al.

Summary: In the 5-year update of ECHELON-2, frontline treatment of PTCL patients with A+CHP continues to show clinically meaningful improvements in PFS and OS compared to CHOP, with continued resolution or improvement of peripheral neuropathy.

ANNALS OF ONCOLOGY (2022)

Add to Collection
Review Immunology

Resistance Mechanisms to Anti-PD Cancer Immunotherapy

Matthew D. Vesely et al.

Summary: The success of anti-PD therapy has revolutionized cancer treatment, but the resistance mechanisms and heterogeneity of responses remain poorly understood. This review discusses recent human cancer data that reveal mechanisms of resistance to anti-PD therapy, including immune-based resistance mechanisms and emerging mechanisms such as alterations in metabolism, microbiota, and epigenetics. Strategies to overcome resistance and the importance of developing additional immunotherapies are also highlighted.

ANNUAL REVIEW OF IMMUNOLOGY (2022)

Add to Collection
Article Hematology

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE

Matthew G. Mei et al.

Summary: This phase 2 trial evaluated the efficacy of PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide as salvage therapy in patients with relapsed/refractory classical Hodgkin lymphoma. The results showed that this treatment approach was well tolerated and effective, leading to a high complete response rate and successful bridging to autologous hematopoietic cell transplantation in most patients.

BLOOD (2022)

Add to Collection
Article Oncology

Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Mingzhi Zhang et al.

Summary: This study investigated the safety and efficacy of autologous CD7-chimeric antigen receptor (CAR) T cells in patients with relapsed and refractory T-ALL/LBL and found promising and durable antitumor response in these patients.

CLINICAL CANCER RESEARCH (2022)

Add to Collection
Article Immunology

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

Karl L. Banta et al.

Summary: Dual blockade of PD-1 and TIGIT is effective in enhancing anti-tumor CD8(+) T cell responses, with concurrent blockade of CD28 and CD226 being necessary for optimal therapeutic effect.

IMMUNITY (2022)

Add to Collection
Article Oncology

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Anjali S. Advani et al.

Summary: The study evaluated the efficacy of Blinatumomab as induction and consolidation therapy in older patients with Philadelphia chromosome-negative B-acute lymphoblastic leukemia. Results showed Blinatumomab had good tolerability and effectiveness in treatment, with some patients achieving complete remission, and encouraging 3-year disease-free survival and overall survival rates.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection
Review Oncology

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

Kevin Pan et al.

Summary: CAR immunotherapy has achieved significant progress in hematological malignancies, but faces challenges in solid tumors. CAR NK cells and CAR macrophages have advantages and limitations. Developing CAR macrophages could be a strategy to overcome hurdles associated with CAR therapy in solid tumors.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection
Article Cardiac & Cardiovascular Systems

Post-transplant lymphoproliferative disorder presenting as supraglottitis following pediatric heart transplantation treated with EBV-specific cytotoxic T-lymphocytes

Sophie Duignan et al.

Summary: This case describes a rare presentation of post-transplant lymphoproliferative disorder (PTLD) in a 4 year-old boy who had undergone heart transplantation. The PTLD developed in an unusual site, the larynx, and required a novel treatment approach including elective tracheostomy and EBV-specific cytotoxic T lymphocytes (CTL) therapy. The treatment was successful and the patient achieved negative biopsy results, allowing for decannulation and discharge.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2022)

Add to Collection
Article Oncology

Management of Immunotherapy-Related Toxicities, Version 1.2022

John A. Thompson et al.

Summary: The NCCN Guidelines for Management of Immunotherapy-Related Toxicities aim to provide guidance on managing adverse events resulting from cancer immunotherapy. The guidelines are developed by an interdisciplinary panel of experts from various fields. This article presents excerpts and reviews of recommendations for managing toxicities related to CAR T-cell therapies.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection
Article Medicine, Research & Experimental

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells

Gils Roex et al.

Summary: CAR T-cell therapy is valuable for treating B-cell malignancies, but can lead to antigen-negative tumor cell outgrowth. Using NK cells as an alternative to T cells and employing a multi-target strategy may be a more effective approach.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Add to Collection
Article Oncology

Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

Deborah A. Katz et al.

Summary: This study assessed the safety and efficacy of blinatumomab consolidation therapy in high-risk DLBCL patients. The findings showed that this treatment was better tolerated compared to previous studies in this patient population.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection
Review Pharmacology & Pharmacy

Stepping forward in antibody-drug conjugate development

Yiming Jin et al.

Summary: Antibody-drug conjugates (ADCs) are cancer therapeutic agents that utilize the specificity of antibodies to target toxic drugs to tumor cells. The recent clinical development of ADCs has shown an increasing trend, with more approved drugs in the market. The in vivo processing of ADCs plays a crucial role in their design and efficacy.

PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection
Article Biochemistry & Molecular Biology

A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CART cells and gilteritinib

Ke-xin Li et al.

Summary: In this study, dual-target FLT3scFv/NKG2D-CART cells were constructed and found to effectively lyse AML cells. The FLT3 inhibitor gilteritinib was also shown to synergistically enhance the therapeutic effect of these CAR-T cells by upregulating NF-kappa B2-dependent NKG2DL expression in AML cells.

MOLECULAR CANCER (2022)

Add to Collection
Article Biochemistry & Molecular Biology

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

Sattva S. Neelapu et al.

Summary: In a phase 2 trial, axicabtagene ciloleucel demonstrated high complete response rate and manageable safety profile as first-line treatment for high-risk large B-cell lymphoma.

NATURE MEDICINE (2022)

Add to Collection
Article Immunology

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+Lymphoma

Wei Sang et al.

Summary: The combination of anti-CD30 CAR-T therapy with PD-1 inhibitor showed enhanced efficacy in patients with relapsed/refractory CD30+ lymphoma. The overall response rate was 91.7%, with minimal toxicities. Cohort 3, which received the combination therapy, achieved a 100% overall response rate and an 80% complete remission rate.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Article Hematology

Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Rajat Bannerji et al.

Summary: The study evaluated the safety and antitumour activity of Odronextamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results demonstrated manageable safety and encouraging preliminary activity. The objective response rate was 51% in patients treated with Odronextamab.

LANCET HAEMATOLOGY (2022)

Add to Collection
Article Hematology

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios A. Dimopoulos et al.

Summary: Elotuzumab plus lenalidomide and dexamethasone did not significantly improve progression-free survival compared to lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who are ineligible for HSCT. Further research is needed to improve frontline treatments.

LANCET HAEMATOLOGY (2022)

Add to Collection
Correction Medicine, Research & Experimental

Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics (vol 23, pg 359, 2021)

Filippos T. Charitidis et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

Add to Collection
Article Oncology

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation

Elizabeth M. Holland et al.

Summary: This study retrospectively analyzed the response and toxicity of patients with B-ALL after reinfusion with CART2. The results showed that approximately 38.9% of patients had objective responses after CART2, including some patients who did not achieve complete remission with CART1. The efficacy of CART2 was influenced by CAR T-cell expansion and antigen modulation. Intensified lymphodepletion may be a strategy to enhance CART2 responses.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection
Review Pharmacology & Pharmacy

Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers

Shih-Cheng Pao et al.

Summary: Cancer immunotherapy has become indispensable in cancer treatment, with a focus on targeting tumor-specific antigens or neoantigens. Advanced technologies have allowed for the identification and application of neoantigens in cancer vaccines. Therapeutic vaccines have shown success in activating the immune system to kill cancer cells.

PHARMACEUTICS (2022)

Add to Collection
Review Oncology

Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials

Yang Xu et al.

Summary: This review discusses the rationale behind incorporating epigenetic therapy into immunotherapy, known as epi-immunotherapy. It provides an update on current clinical trials in hematological and solid malignancies and outlines future challenges and strategies in the field of cancer epi-immunotherapy.

CANCER COMMUNICATIONS (2022)

Add to Collection
Article Medicine, Research & Experimental

Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products

Lipei Shao et al.

Summary: The study found differences in integration patterns, insertion hotspots, and effects on gene expression between lentiviral and gamma-retroviral vectors used in CAR T-cell products, which provide a foundation for further analysis.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Add to Collection
Article Medicine, General & Internal

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael J. Dickinson et al.

Summary: Glofitamab therapy is effective for DLBCL, but more than half of the patients experience grade 3 or 4 adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Medicine, General & Internal

Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody

Ajai Chari et al.

Summary: Talquetamab treatment exhibited common adverse events like cytokine release syndrome, skin-related events, and dysgeusia, which were primarily low-grade; however, the drug induced substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Hematology

Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies

Abdullah Freiwan et al.

Summary: CD7(-) T cells can serve as a promising subset for CAR-T cell therapy of T-ALL and other hematological malignancies.

BLOOD (2022)

Add to Collection
Article Cell & Tissue Engineering

CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma

Qian Cheng et al.

Summary: This study aimed to evaluate the effectiveness and toxicity of CD20 CAR T cells in rituximab-treated R/R B-NHL patients. The results showed that all enrolled patients achieved clinical responses with tolerable toxicities. However, patients who had received rituximab within 3 months had a poorer prognosis.

CYTOTHERAPY (2022)

Add to Collection
Article Oncology

CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.

Ravi Vij et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection
Article Oncology

MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma.

Rafael Fonseca et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection
Letter Oncology

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia

Xin Jin et al.

Summary: This study evaluates the efficacy and safety of CLL-1 CAR-T cell therapy in adults with R/R AML. All patients developed cytokine release syndrome (CRS), but none developed CAR-T cell-related encephalopathy syndrome (CRES). Despite severe pancytopenia in all patients, a 70% complete response (CR) or CR with incomplete hematologic recovery (CRi) rate was achieved.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection
Article Medicine, General & Internal

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar et al.

LANCET (2022)

Add to Collection
Article Oncology

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison Sehgal et al.

Summary: The study evaluated the efficacy and safety of lisocabtagene maraleucel as second-line treatment for patients with large B-cell lymphoma, showing potential therapeutic effects with some treatment-related adverse events.

LANCET ONCOLOGY (2022)

Add to Collection
Article Oncology

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde et al.

Summary: The study evaluated the safety and efficacy of fixed-duration mosunetuzumab in patients with relapsed or refractory follicular lymphoma. The results showed that mosunetuzumab has a favorable safety profile and induces high rates of complete remissions.

LANCET ONCOLOGY (2022)

Add to Collection
Article Oncology

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial

Heiner Zimmermann et al.

Summary: This study investigated the efficacy of a modified risk-stratification strategy in adult SOT recipients with CD20-positive PTLD. The results showed that this strategy achieved a favorable event-free survival rate in the low-risk group, while immunotherapy intensification in the very-high-risk group had disappointing results.

LEUKEMIA (2022)

Add to Collection
Article Oncology

Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction

Penglei Jiang et al.

Summary: CAR-T cell therapy has achieved remarkable success in treating hematopoietic malignancies. However, CAR-T cell exhaustion leading to high relapse rate and poor persistence remains a major barrier. This study investigated the mechanisms of CAR-T exhaustion through single-cell ATAC-seq and identified BATF and IRF4 as pivotal regulators. Knockdown of BATF or IRF4 improved killing ability, inhibited exhaustion, and prolonged CAR-T cell persistence in vivo.

LEUKEMIA (2022)

Add to Collection
Article Medicine, General & Internal

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau et al.

Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Medicine, General & Internal

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma

Stephen M. Ansell et al.

Summary: The study found that using A+AVD for the treatment of stage III or IV Hodgkin's lymphoma provides a survival advantage over ABVD.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Review Immunology

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Xiaomin Zhang et al.

Summary: CAR-T cell therapy has shown significant success in the treatment of hematological malignancies, but challenges remain in terms of adverse events and resistance mechanisms.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Article Hematology

Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients

Gautam Borthakur et al.

Summary: Fludarabine, cytarabine, GCSF (FLAG)-based induction/consolidation with gemtuzumab ozogamicin (FLAG-GO) achieves higher remission rates in core binding factor (CBF) acute myelogenous leukemia compared to FLAG-IDA. FLAG-GO regimen results in better clinical outcomes and deeper molecular clearance by qPCR assessment of fusion transcripts.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection
Article Hematology

Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD

Xiaohui Kong et al.

Summary: Expansion of CXCR5-PD-1(hi) peripheral T-helper (Tph) cells in patients with chronic graft-versus-host disease (cGVHD) is associated with disease severity. These cells promote memory B-cell differentiation and immunoglobulin G production through interleukin 21 (IL-21). Tph cells in the blood and tissue-resident T-helper (Trh) cells in cGVHD target tissues share T-cell receptor alpha and beta repertoires, and their trafficking between the blood and target tissues is controlled by IL-21R-BCL6 signaling and T-bet. The development and expansion of Tph and Trh cells are important in the pathogenesis of cGVHD.

BLOOD (2022)

Add to Collection
Article Hematology

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL

Lijun Zhao et al.

Summary: This study developed a novel approach for enhancing antitumor efficacy and overcoming immune escape by designing a CD19/CD22/CD3 trispecific antibody (tsAb). The optimized tsAb showed superior ability in inducing T-cell-specific cytotoxicity and cytokine production against CD19+ and/or CD22+ tumor cells compared to other tsAb formats. It also demonstrated significantly enhanced anti-tumor efficacy and the ability to overcome immune escape.

BLOOD (2022)

Add to Collection
Article Hematology

OAB-007: Updated clinical and correlative results from the Phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and/or refractory multiple myeloma

Noopur Raje et al.

Clinical Lymphoma Myeloma & Leukemia (2022)

Add to Collection
Article Hematology

MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis

Hang Quach et al.

Clinical Lymphoma Myeloma & Leukemia (2022)

Add to Collection
Article Hematology

P-017: MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant

María-Victoria Mateos et al.

Clinical Lymphoma Myeloma & Leukemia (2022)

Add to Collection
Article Hematology

MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma

Jeffrey A. Zonder et al.

Clinical Lymphoma Myeloma & Leukemia (2022)

Add to Collection
Article Urology & Nephrology

In vitro and in vivo evidence that the switch from c for updates calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder

Constantin J. Thieme et al.

Summary: Post-transplant lymphoproliferative disorder is a severe complication of immunosuppression following transplantation. This study investigated the impact of different immunosuppressants on EBV-antigen-specific T cells and lymphoblastoid cell lines. The results showed that rapamycin and mycophenolic acid inhibited lymphoblastoid cell-line proliferation, prednisolone and rapamycin-treated T cells exhibited normal cytokine production, and tacrolimus and cyclosporin A suppressed T-cell function.

KIDNEY INTERNATIONAL (2022)

Add to Collection
Review Biochemistry & Molecular Biology

The journey of CAR-T therapy in hematological malignancies

Junru Lu et al.

Summary: Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of hematological malignancies, but some patients may experience relapse, leading to the need for novel strategies to overcome resistance and relapse mechanisms. Significant technological advancements have been made, and the clinical application of CAR-T cell therapy is constantly being explored and improved.

MOLECULAR CANCER (2022)

Add to Collection
Article Multidisciplinary Sciences

PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program

Masao Hashimoto et al.

Summary: The study showed that combination therapy with PD-1 blockade and IL-2 during chronic lymphocytic choriomeningitis virus infection significantly alters the differentiation program of CD8(+) T cells, resulting in the generation of highly functional effector CD8(+) T cells that mediate viral control, thus providing a new perspective for cancer treatment.

NATURE (2022)

Add to Collection
Article Multidisciplinary Sciences

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

Jiqin Zhang et al.

Summary: A two-in-one approach to generate non-viral, gene-specific targeted CAR-T cells through CRISPR-Cas9 was successfully developed, demonstrating feasibility and efficacy in a preclinical study. An innovative type of anti-CD19 CAR-T cell with PD1 integration showed superior ability to eradicate tumor cells.

NATURE (2022)

Add to Collection
Review Urology & Nephrology

Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury

Ben Sprangers et al.

Summary: Immune checkpoint inhibitors (ICIs) have had a significant impact on cancer treatment, but their use can lead to immune-related adverse events, including acute kidney injury. This review provides an overview of the symptoms, biochemical markers, and potential underlying mechanisms of ICI-associated acute kidney injury, and proposes a diagnostic and management approach.

NATURE REVIEWS NEPHROLOGY (2022)

Add to Collection
Article Medicine, General & Internal

GPRC5D-Targeted CAR T Cells for Myeloma

Sham Mailankody et al.

Summary: The study demonstrates that GPRC5D is an active immunotherapeutic target in multiple myeloma, and GPRC5D-targeted CAR T-cell therapy shows promising efficacy in heavily pretreated patients, including those who relapsed after BCMA CAR T-cell therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Multidisciplinary Sciences

USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer

Dongni Shi et al.

Summary: This study reveals that USP14, a proteasome-associated deubiquitinating enzyme, regulates the post-translational modification of IDO1 and plays a role in suppressing antitumor immunity in colorectal cancer. Inhibiting USP14 can decrease IDO1 expression and reverse T-cell dysfunction, suggesting that targeting USP14 may be a promising strategy for CRC immunotherapy.

NATURE COMMUNICATIONS (2022)

Add to Collection
Article Hematology

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial

Elias Jabbour et al.

Summary: This study investigated the incorporation of blinatumomab into front-line therapy for acute lymphocytic leukaemia and found that it improved outcomes and resulted in encouraging long-term survival.

LANCET HAEMATOLOGY (2022)

Add to Collection
Article Hematology

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Hartmut Goldschmidt et al.

Lancet Haematology (2022)

Add to Collection
Meeting Abstract Hematology

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) plus Lenalidomide (Len) Vs Tafa plus Len in Relapsed or Refractory DLBCL

Krish Patel et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

MajesTEC-7: A Phase 3, Randomized Study of Teclistamab plus Daratumumab plus Lenalidomide (Tec-DR) Versus Daratumumab plus Lenalidomide plus Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

Amrita Y. Krishnan et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Ola Landgren et al.

BLOOD (2022)

Add to Collection
Editorial Material Hematology

Chronic GVHD on the move

Antonia M. S. Mueller

Summary: The study reveals a new pathophysiologic link between autoimmune diseases and chronic GVHD, showing the clonal relationship and trafficking abilities of peripheral T helper cells and tissue-resident T helper cells between blood and target organs.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+Acute Myeloid Leukemia (AML)

David A. Sallman et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Sandy W. Wong et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Proteomic and Transcriptomic Profiling Reveals Insights into Mechanisms of Leukemic Immune Escape

Sean Tracy et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Binod Dhakal et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma

Eliza Hawkes et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Sanjay R. Mohan et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Krish Patel et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma

Christopher J. Ferreri et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Naval Daver et al.

BLOOD (2022)

Add to Collection
Review Oncology

Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis

Xiao-Tong Zhang et al.

Summary: This study evaluated the incidence of cardiotoxicity related to immune checkpoint inhibitor (ICI) therapies for lung cancer. The results showed that single ICI did not increase the risk of cardiotoxicity compared to chemotherapy, while single ICI plus chemotherapy increased the risk of cardiotoxicity by 67% compared to chemotherapy alone. Combination immunotherapy did not increase the risk of cardiotoxicity compared to single ICI.

CANCER CELL INTERNATIONAL (2022)

Add to Collection
Article Oncology

Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective

Xiaohui Si et al.

Summary: Chimeric Antigen-Receptor (CAR) T-cell therapies have shown significant efficacy in treating certain cancers, but they can also lead to adverse effects such as hematologic cytopenias, which are characterized by a reduction in mature blood cells and an increased risk of infections and other complications. This review summarizes the symptoms, causes, risk factors, and management of cytopenias, and delves into the cellular and molecular mechanisms underlying the development of cytopenias following CAR T-cell therapy.

CANCER LETTERS (2022)

Add to Collection
Meeting Abstract Hematology

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Elena Zamagni et al.

BLOOD (2022)

Add to Collection
Meeting Abstract Hematology

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Sebastian Grosicki et al.

BLOOD (2022)

Add to Collection
Article Cell Biology

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

Yongxian Hu et al.

Summary: This study developed healthy donor-derived CD7-targeting allogeneic CAR-T cells with genetic modifications and conducted a phase I clinical trial. The results demonstrated the encouraging safety and efficacy profiles of the RD13-01 allogeneic CAR-T cells for CD7(+) tumors.

CELL RESEARCH (2022)

Add to Collection
Article Medicine, Research & Experimental

An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma

Meijie Tian et al.

Summary: This study identified high-activity CARs against neuroblastoma using multiple approaches and demonstrated the potential of targeting multiple TAAs with BiCisCAR to overcome heterogenous expression in solid tumors. The multimodal approach integrating competitive expansion, P-COCC, and cytotoxicity assays proved to be effective in identifying potent CARs.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Add to Collection
Review Oncology

Natural killer cells in antitumour adoptive cell immunotherapy

Tamara J. Laskowski et al.

Summary: This review provides an overview of NK cell-based immunotherapies, discussing strategies to increase NK cell cytotoxicity and persistence and highlighting the current challenges and future opportunities for the design of next-generation NK cell therapies.

NATURE REVIEWS CANCER (2022)

Add to Collection
Article Medicine, Research & Experimental

A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level

Rita Pfeifer et al.

Summary: The study demonstrated the importance of 3D micro CT/BLT for whole-body cell therapy monitoring and investigating CAR T cell pharmacokinetics, combining LSFM and MICS for assessing intratumoral therapeutic cell distribution and status.

THERANOSTICS (2022)

Add to Collection
Article Immunology

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma

Mengyi Du et al.

Summary: CAR-T cell therapy is a promising approach for treating relapsed or refractory hematological malignancies, but challenges such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and hematologic toxicity still remain. We report 3 cases of refractory thrombocytopenia in relapsed/refractory multiple myeloma patients treated with CAR-T cell therapy, who were successfully treated with standard therapy for immune thrombocytopenia.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection
Review Immunology

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

Emma C. Morris et al.

Summary: CAR T cell therapy has revolutionized the field of cancer treatment, but significant toxicities can occur in up to one-third of patients. The most common toxicities include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Understanding their pathophysiology is crucial for developing novel therapeutics for prevention and management.

NATURE REVIEWS IMMUNOLOGY (2022)

Add to Collection
Article Oncology

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Gerald G. Wulf et al.

Summary: Combination therapy of alemtuzumab and CHOP in PTCL patients improved short-term response rates but increased the risk of infections due to treatment-related toxicity, ultimately not improving survival. Male sex and bulky disease were significant risk factors for EFS, PFS, and OS.

LEUKEMIA (2021)

Add to Collection
Article Oncology

CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression

Kristen Fousek et al.

Summary: Chimeric antigen receptor (CAR) T-cells targeting CD19 have shown effectiveness in treating B-lineage acute lymphoblastic leukemia (BL-ALL), but a significant number of patients relapse with CD19(-) disease. This study demonstrates that creating a CD19/20/22-targeting CAR T-cell can effectively target CD19(-) escape leukemia cells, forming dense immune synapses at the subcellular level.

LEUKEMIA (2021)

Add to Collection
Review Medicine, Research & Experimental

Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity

Andrea Schmidts et al.

Summary: CAR-T cell therapy has revolutionized the treatment of hematological malignancies, particularly acute lymphoblastic leukemia and large B cell lymphoma. However, it is associated with toxicities such as cytokine release syndrome and ICANS, which require further research and attention to manage effectively.

ANNUAL REVIEW OF MEDICINE, VOL 72, 2021 (2021)

Add to Collection
Letter Hematology

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma

Maxime Fayon et al.

HAEMATOLOGICA (2021)

Add to Collection
Review Oncology

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

M-L Schubert et al.

Summary: CAR T-cell therapy targeting CD19-expressing B cells has shown promising results in treating refractory and/or relapsed B-cell malignancies, but also presents challenges such as cytokine release syndrome and neurotoxicity syndrome. Optimal management strategies for the side-effects associated with CAR T-cell therapy are crucial as it expands into other diseases in hematology and oncology.

ANNALS OF ONCOLOGY (2021)

Add to Collection
Article Oncology

Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

B. Eichhorst et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection
Article Oncology

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies

Philippe Armand et al.

Summary: This study examined the safety and efficacy of combining PD-1 blockade with other pathways inhibitors in lymphoid malignancies. While some combinations showed effectiveness in cHL patients, overall, the combinations did not significantly improve upon the efficacy of single-agent nivolumab in the diseases studied.

LEUKEMIA (2021)

Add to Collection
Article Hematology

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy et al.

Summary: This study presents the results of a multicenter, open-label, phase 1/2 study of flotetuzumab in 88 adults with relapsed/refractory AML, showing clinical benefits in PIF/ER patients and encouraging evidence of activity. Flotetuzumab represents an innovative experimental approach associated with acceptable safety.

BLOOD (2021)

Add to Collection
Article Hematology

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL

Yaqi Zhao et al.

Summary: This study investigated the efficacy of blinatumomab in patients with B-progenitor acute lymphoblastic leukemia (B-ALL) and found that both tumor-intrinsic and -extrinsic factors influence blinatumomab response. CD19 mutations were commonly detected in CD19(-) relapse during blinatumomab treatment, and the identification of the CD19 ex2part splice variant represents a new biomarker predictive of blinatumomab therapy failure.

BLOOD (2021)

Add to Collection
Article Hematology

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Erica Brivio et al.

Summary: This phase 1 study investigated the efficacy and safety of inotuzumab ozogamicin in pediatric patients with acute lymphoblastic leukemia, establishing the recommended phase 2 dose as 1.8 mg/m(2). The treatment showed promising efficacy and good tolerability, with potential clinical implications.

BLOOD (2021)

Add to Collection
Article Oncology

CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma

Hui Liu et al.

Summary: The study demonstrates that CD19-PD-1/CD28-CAR T cells have better efficacy in treating PD-L1 positive B-cell lymphoma compared to CD19-CAR T cells. Among 17 patients who received CAR T therapy, 58.8% had objective response with 41.2% achieving complete remission at a median follow-up of 15 months. No severe neurological toxicity or cytokine release syndrome was observed.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Review Oncology

Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies

Junji Tanaka

Summary: CAR-NK cells, with potent anti-leukemia/lymphoma effects and better proliferative capacity, have shown promise as an off-the-shelf allogeneic cellular therapy for overcoming intractable hematological malignancies. The safety and efficacy of CAR-NK cells, particularly in HLA-mismatched allogeneic cord blood-derived CD19 CAR-NK cell therapy for CD19-positive hematological malignancies, have been reported but the durability of clinical effects remains to be clarified.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection
Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

Add to Collection
Article Hematology

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani et al.

Summary: Loncastuximab tesirine, an antibody-drug conjugate, shows promising efficacy and safety in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, especially for certain specific lymphoma subtypes. This study suggests that loncastuximab tesirine could be a valuable treatment option for these patients and warrants further investigation in phase 2 trials.

BLOOD (2021)

Add to Collection
Article Hematology

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Di Wang et al.

Summary: CT103A, a fully human BCMA-specific CAR T-cell therapy, has shown safety and high efficacy in patients with relapsed/refractory multiple myeloma, including those who had prior exposures to murine BCMA CAR therapy. Its overall response rate reaches 100%, with a significant portion achieving complete response or stringent complete response. Hematologic toxicities are common adverse events, but no immune effector cell-associated neurotoxicity syndrome was observed. Detection of CAR transgenes and median CAR transgene persistence support the potential of CT103A as a promising therapy for RRMM.

BLOOD (2021)

Add to Collection
Meeting Abstract Hematology

Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

Alexander Lesokhin et al.

BLOOD (2021)

Add to Collection
Meeting Abstract Hematology

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

Guillermo Garcia-Manero et al.

BLOOD (2021)

Add to Collection
Meeting Abstract Hematology

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non- Hodgkin's Lymphoma: Initial Clinical Results

Amitkumar Mehta et al.

BLOOD (2021)

Add to Collection
Meeting Abstract Hematology

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Lazaros J. Lekakis et al.

BLOOD (2021)

Add to Collection
Article Hematology

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies

Michael Dickinson et al.

BLOOD (2021)

Add to Collection
Meeting Abstract Hematology

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic `Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+B-ALL

Nitin Jain et al.

BLOOD (2021)

Add to Collection
Meeting Abstract Hematology

A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Shaji Kumar et al.

BLOOD (2021)

Add to Collection
Meeting Abstract Hematology

Preliminary Results from the Flu/Cy/Alemtuzumab Arm of the Phase I BALLI-01 Trial of UCART22, an AntiCD22 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD22+B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain et al.

BLOOD (2021)

Add to Collection
Article Medicine, Research & Experimental

Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response

Michelle von Locquenghien et al.

Summary: Interferons (IFNs) play a critical role in regulating epithelial cell functions and immune system regulation, impacting both tumor-intrinsic and -extrinsic mechanisms in cancer. Understanding the dynamic responses to IFN can lead to novel immunotherapeutic strategies to overcome pro-tumorigenic effects of IFNs while utilizing their anti-tumor immunity. These insights also shed light on immunotherapy-mediated immunoediting and the dual opposing roles of IFNs in immune checkpoint blockade response.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection
Article Oncology

Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion

Wenli Fang et al.

Summary: The study reveals that PGRN promotes M2 polarization and PD-L1 expression by activating the STAT3 signaling pathway. Furthermore, through the PD-1/PD-L1 interaction, PGRN can facilitate immune escape in breast tumors.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Oncology

HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells

Vianihuini Figueroa-Vazquez et al.

Summary: HDP-101, an anti-BCMA antibody conjugated with an amanitin derivative, demonstrates high efficacy against multiple myeloma cells while sparing BCMA-negative cells. It induces tumor regression in animal models at low doses and shows good tolerability, suggesting a promising therapeutic approach to overcome drug resistance in this disease.

MOLECULAR CANCER THERAPEUTICS (2021)

Add to Collection
Article Multidisciplinary Sciences

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming

Yao Wang et al.

Summary: The study demonstrates that pre-treatment of CAR T cells with a DNA methyltransferase inhibitor enhances anti-tumor activities, cytokine production, and proliferation, allowing for effective eradication of tumors at low doses and improved response to tumor rechallenge.

NATURE COMMUNICATIONS (2021)

Add to Collection
Article Oncology

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Bianca D. Santomasso et al.

Summary: This guideline aims to provide guidance on the management of immune-related adverse events in patients treated with CAR T-cell therapy, developed by a multidisciplinary team based on expert consensus. Management of CAR T-cell-related toxicities includes supportive care and pharmacologic interventions, such as tocilizumab and corticosteroids, for severe symptoms.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Review Hematology

Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?

Carlota Gudiol et al.

Summary: CAR T-cell therapy shows promise for refractory or relapsed B-cell malignancies, with increased risk of infectious complications managed by anti-interleukin-6 antibodies, corticosteroids, and other methods.

LANCET HAEMATOLOGY (2021)

Add to Collection
Article Oncology

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

Heng Mei et al.

Summary: Bispecific BM38 CAR-T cells showed strong efficacy in patients with refractory or relapsed multiple myeloma (RRMM), with good clinical responses and manageable toxicities.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Oncology

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity

Zhaoming Wang et al.

Summary: Research suggests that treatment with anti-CD3 x anti-cancer bispecific antibodies (bsAbs) may enhance T cell help, maintaining long-term NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Review Hematology

Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy

Jochen Buechner et al.

Summary: Cytokine release syndrome (CRS) associated with CAR-T therapies can lead to coagulopathy and hypofibrinogenemia. Management of hypofibrinogenemia with fibrinogen concentrate or cryoprecipitate replacement is effective in avoiding severe bleeding events. Monitoring fibrinogen levels in patients with moderate or severe CRS is crucial for patient safety.

BLOOD ADVANCES (2021)

Add to Collection
Article Hematology

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Michael D. Jain et al.

Summary: This study found that in LBCL tumors, IFN signaling is associated with the expression of immune checkpoint ligands, and it is related to lack of durable response to CAR-T therapy. Immune dysregulation promotes axi-cel resistance via multiple mechanistic programs, including insufficient axi-cel expansion due to circulating M-MDSC and tumor IFN signaling.

BLOOD (2021)

Add to Collection
Article Oncology

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Yongxian Hu et al.

Summary: The study successfully developed CRISPR-edited universal CAR-T cells as a novel therapy for r/r ALL. Results showed that this therapy has a manageable safety profile and prominent antileukemia activity, providing an alternative treatment option for patients.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Medicine, General & Internal

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial

Patrick A. Brown et al.

Summary: In children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL, postreinduction treatment with blinatumomab compared with chemotherapy, followed by transplant, did not result in a statistically significant difference in disease-free survival. However, study interpretation is limited by early termination with possible underpowering for the primary end point.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection
Article Medicine, General & Internal

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial

Franco Locatelli et al.

Summary: This study compared the effects of blinatumomab with consolidation chemotherapy as a third consolidation block before allogeneic hematopoietic stem cell transplant in children with high-risk first-relapse B-ALL. The results showed that, compared to chemotherapy, treatment with blinatumomab significantly improved event-free survival in children with high-risk first-relapse B-ALL.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection
Article Oncology

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Robert J. Kreitman et al.

Summary: Moxetumomab pasudotox demonstrated a high rate of durable responses and minimal residual disease negativity in patients with relapsed/refractory hairy cell leukemia, with a manageable safety profile.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Oncology

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla et al.

LANCET ONCOLOGY (2021)

Add to Collection
Letter Oncology

Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature

Ajay Major et al.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection
Review Oncology

Immunogenicity of CAR T cells in cancer therapy

Dimitrios L. Wagner et al.

Summary: CAR T cells have shown significant clinical responses in patients with certain advanced-stage B cell malignancies, but some patients may experience anti-CAR immune responses leading to treatment failure. Strategies to monitor and reduce the risks of anti-CAR immune responses are needed to improve CAR T cell therapy outcomes.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection
Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection
Article Multidisciplinary Sciences

Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy

Tracy Rabilloud et al.

Summary: The study demonstrates that CD19-negative leukemic subclones may already exist before CAR-T cell therapy in patients with B-ALL, leading to potential relapse. By utilizing single-cell RNA sequencing, pre-existing CD19 negative subclones were identified, highlighting the possibility of assessing the risk of targeted therapy failure.

NATURE COMMUNICATIONS (2021)

Add to Collection
Article Multidisciplinary Sciences

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

Mehmet Kemal Samur et al.

Summary: Relapse following BCMA targeted CAR T-cell therapy in multiple myeloma patients is often due to biallelic loss of BCMA, which hinders the proliferation of CAR T cells and results in lack of response to retreatment. Single cell genomic characterization is essential for detecting BCMA gene alterations to improve treatment outcomes.

NATURE COMMUNICATIONS (2021)

Add to Collection
Article Hematology

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

Jeff P. Sharman et al.

Summary: The study found that adding ublituximab to ibrutinib therapy in high-risk patients resulted in a significantly higher overall response rate without affecting the safety profile of ibrutinib monotherapy.

LANCET HAEMATOLOGY (2021)

Add to Collection
Article Oncology

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

Rafaela Kramer et al.

Summary: Hematological immune-related adverse events (hem-irAE) are rare but severe complications of immune checkpoint inhibitors (ICI) therapy, including thrombocytopenia and leukopenia, which can lead to persistent changes or even fatal outcomes. Treatment may require second-line immunosuppression in addition to discontinuation of ICI and corticosteroids.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection
Article Hematology

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

Catherine Diefenbach et al.

Lancet Haematology (2021)

Add to Collection
Review Endocrinology & Metabolism

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside

Linda Wu et al.

Summary: Immune checkpoint inhibitors have greatly impacted oncological therapy, but have also led to a new set of immune related adverse events, including checkpoint inhibitor-related autoimmune diabetes. Studying autoimmune diabetes may help in identifying new therapeutic strategies.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

LEMZOPARLIMAB (TJ011133), AN ANTI-CD47 ANTIBODY, WITH/WITHOUT DEXAMETHASONE PLUS ANTI-MYELOMA REGIMENS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PHASE 1B DOSE ESCALATION AND EXPANSION STUDY

Edward Stadtmauer et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells

Emiliano Roselli et al.

Summary: The study demonstrates that combining 4-1BB with an optimized form of CD28 for co-stimulation is an effective way to enhance CAR T cell function. Both mono-specific and bi-specific versions of this design show improved expansion, persistence, and resistance to exhaustion in vitro and in vivo.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Oncology

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities

Ilias Christodoulou et al.

Summary: The study demonstrates that engineering NK cells to express CARs and IL-15 can enhance their anti-AML activity. However, this modification also comes with potential systemic toxicities.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with different subtypes of thyroid immune-related adverse events having unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer progression free survival and overall survival, while hypothyroidism showed no association with cancer outcomes. Multiple distinct phenotypes of thyroid irAEs suggest potentially different etiologies for thyrotoxicosis and hypothyroidism.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection
Article Oncology

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings et al.

Summary: The study evaluated the use of glofitamab in relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) patients. The results showed favorable activity of glofitamab in patients with predominantly refractory, aggressive B-NHL, with frequent and durable complete responses and a predictable and manageable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Review Oncology

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Ying Gong et al.

Summary: NK cells, especially CAR-NK cells, play a crucial role in cancer treatment. Advances in CAR-NK technology show promising potential in efficiently targeting cancer cells with reduced side effects. These developments contribute to improving cancer treatment strategies.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Review Oncology

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

Zheng Tian et al.

Summary: Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. Bispecific antibodies such as BiTEs have shown potential in recruiting T cells to tumor cells for immunotherapy, with a focus on improving efficacy and safety in clinical treatments for hematologic malignancies.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Oncology

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi et al.

Summary: Loncastuximab tesirine shows substantial antitumor activity and acceptable safety profile in patients with relapsed or refractory DLBCL, potentially offering a new therapeutic option for heavily pretreated individuals.

LANCET ONCOLOGY (2021)

Add to Collection
Review Endocrinology & Metabolism

Endocrine toxicities of immune checkpoint inhibitors

Jordan J. Wright et al.

Summary: Immune checkpoint inhibitors (ICIs) have become a cornerstone of cancer therapeutics, but can also cause toxicities in various organs known as immune-related adverse events. ICIs can lead to endocrinopathies involving the thyroid, pituitary, adrenal glands, and pancreas, which are common and sometimes fatal.

NATURE REVIEWS ENDOCRINOLOGY (2021)

Add to Collection
Review Biotechnology & Applied Microbiology

Leveraging Single-Cell Sequencing for Chimeric Antigen Receptor T Cell Therapies

Rocio Castellanos-Rueda et al.

Summary: Chimeric antigen receptor (CAR)-T cell therapies against cancer have made progress, but subpar efficacy remains an obstacle. Analyzing the transcriptome can provide insights into CAR-induced T cell activation.

TRENDS IN BIOTECHNOLOGY (2021)

Add to Collection
Article Oncology

Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells

Zhiliang Bai et al.

Summary: Using single-cell mRNA sequencing and CITE-seq, researchers conducted multiomics characterization of CAR T cells from healthy donors and patients with acute lymphoblastic leukemia, revealing heterogeneities in transcriptional, phenotypic, functional, and metabolic profiles between donor and patient CAR T cells. Donor CAR T cells exhibited more pronounced activation levels upon CD19 stimulation.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Review Health Care Sciences & Services

Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas

Ross Salvaris et al.

Summary: The treatment landscape of B-cell lymphomas is evolving with the development of novel agents, with bispecific antibodies playing an increasingly important role. Several bispecific antibodies have entered clinical trials, including studies on CD20/CD3, and have shown promising overall response rates.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection
Article Hematology

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Kai Rejeski et al.

Summary: Hematotoxicity is a common adverse event in CAR T-cell therapy, with baseline thrombocytopenia and hyperferritinemia being significant predictive markers. The CAR-HEMATOTOX model can accurately predict the occurrence of severe neutropenia.

BLOOD (2021)

Add to Collection
Article Hematology

Characterization of HLH-like manifestations as a CRS variant in CD22 CAR T cells

Daniel A. Lichtenstein et al.

Summary: In a subset of patients with cytokine release syndrome (CRS), chimeric antigen receptor (CAR) T-cell toxicities resembling hemophagocytic lymphohistiocytosis (HLH) can occur, known as carHLH. This study comprehensively characterized the manifestations and timing of carHLH, highlighting factors such as preinfusion natural killer cell lymphopenia and higher bone marrow T-cell:NK cell ratio associated with its development. Additionally, carHLH was characterized by persistent elevation of HLH-associated inflammatory cytokines following CAR T-cell expansion.

BLOOD (2021)

Add to Collection
Review Oncology

Mechanisms of Therapeutic Antitumor Monoclonal Antibodies

Li-Chung Tsao et al.

Summary: Monoclonal antibodies are a crucial component of cancer therapy, primarily working by stimulating innate immune effector processes. Different therapeutic mAbs targeting various tumor antigens have shown significant efficacy, with a key role of innate immune-mediated mechanisms observed in mAb therapies against different types of cancer, including HER2(+) solid tumors.

CANCER RESEARCH (2021)

Add to Collection
Article Oncology

Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells

Zhigang Nian et al.

Summary: CAR-T therapy for acute myeloid leukemia (AML) has shown limited efficacy in clinical trials. This study identified aberrant mTORC1 signaling in CAR-T cells as a potential cause for this limited efficacy. Pretreatment with rapamycin to modulate mTORC1 activity enhanced the bone marrow infiltration capacity and anti-AML efficacy of CAR-T cells.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Urology & Nephrology

Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation

Matthew H. Abramson et al.

Summary: AKI is a major complication of allogeneic hematopoietic stem cell transplantation, increasing risk of nonrelapse mortality. Risk factors include exposure to calcineurin inhibitors and graft versus host disease, while T cell-depleted transplants and higher serum albumin levels can reduce the risk of AKI.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection
Article Oncology

Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531

Jessica A. Pollard et al.

Summary: Using the CD33-targeted agent gemtuzumab ozogamicin (GO) improved event-free survival (EFS) and reduced relapse risk (RR) for pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML). Incorporating GO into treatment may lead to better outcomes, especially when combined with hematopoietic stem cell transplant (HSCT).

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

Ryotaro Nakamura et al.

Summary: The study compared allogeneic hematopoietic cell transplantation (HCT) with other treatments for patients aged 50-75 with intermediate-2 or high-risk de novo MDS, and found that HCT with a matched donor significantly improved 3-year overall survival rate and leukemia-free survival rate.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+NHL.

Bijal D. Shah et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial

Jing Pan et al.

Summary: Donor-derived anti-CD7 CAR T cells showed efficient expansion and high complete remission rate in patients with r/r T-ALL, with manageable adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Article Immunology

Single-cell imaging of T cell immunotherapy

Chuan Yan et al.

Summary: This study utilized optically clear immunocompromised zebrafish models engrafted with fluorescent-labeled human cancers and various T cell immunotherapies to visualize T cell immune responses at single-cell resolution in real time. Differences in kinetics of T cell infiltration, tumor cell engagement, and killing were identified among the immunotherapies, leading to early endpoint analysis for predicting therapy responses. EGFR-targeted immunotherapies were established as a powerful approach to eradicate rhabdomyosarcoma muscle cancers, suggesting the potential of assessing a broader range of T cell immunotherapies in this disease.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection
Letter Oncology

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Qingya Cui et al.

Summary: The study demonstrated the potential efficacy and safety of CD38-targeted CAR-T cells in treating relapsed AML patients by eliminating CD38 positive blasts without off-target effects, although the risk of relapse still exists.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection
Article Medicine, General & Internal

Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z. Usmani et al.

Summary: The study evaluated the safety, tolerability, and efficacy of the novel therapy teclistamab for relapsed or refractory multiple myeloma. The results showed promising response rates and durable efficacy in patients treated at the recommended phase 2 dose, with good overall safety profiles.

LANCET (2021)

Add to Collection
Article Medicine, General & Internal

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau et al.

Summary: The study showed that the addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population.

LANCET (2021)

Add to Collection
Article Medicine, General & Internal

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal D. Shah et al.

Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.

LANCET (2021)

Add to Collection
Article Medicine, General & Internal

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings et al.

Summary: This study aimed to evaluate the safety and recommended dose of a novel bispecific antibody epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results showed that the full dose of 48 mg was identified as the recommended phase 2 dose, and no maximum tolerated dose was reached during the treatment. Epcoritamab demonstrated good antitumor activity in some patients during the study.

LANCET (2021)

Add to Collection
Article Medicine, General & Internal

Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesus G. Berdeja et al.

Summary: The study aimed to evaluate the safety and clinical activity of cilta-cel in patients with relapsed or refractory multiple myeloma, and the results showed that cilta-cel treatment achieved good efficacy and safety with short treatment duration, deep response, and long duration of response.

LANCET (2021)

Add to Collection
Article Biochemistry & Molecular Biology

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Jay Y. Spiegel et al.

Summary: Despite impressive progress in CAR-T cell therapy, more than 50% of patients treated with CD19-targeting CAR-T cells experience disease progression, often associated with antigen loss. To address this issue, researchers tested a bispecific CAR targeting CD19 and/or CD22, which showed high efficacy in preventing relapse in patients with B-ALL and LBCL. Antigen loss was identified as a major cause of CAR T cell resistance, emphasizing the importance of engineering multi-specific CAR T cells with equivalent potency and cytokine production as a quality indicator for potency.

NATURE MEDICINE (2021)

Add to Collection
Article Multidisciplinary Sciences

Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells

Murat Tekguc et al.

Summary: Regulatory T cells reduce the expression of CD80/CD86 on antigen-presenting cells through CTLA-4-dependent trogocytosis, inhibiting T cell immune responses. This mechanism can have dual suppressive effects, limiting CD80/CD86 costimulation to naive T cells and increasing free PD-L1 available for the inhibition of PD-1-expressing effector T cells.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection
Review Immunology

Exploiting Single-Cell Tools in Gene and Cell Therapy

Daniel Bode et al.

Summary: The rapid development of single-cell molecular tools has enabled in-depth exploration of individual cell genome, transcriptome, epigenome, and proteome, unraveling the molecular networks of complex biological systems. This technology plays a crucial role in fields with cellular heterogeneity such as stem cell biology, immunology, and tumor cell biology. Moreover, single-cell omics technologies have contributed to the identification of novel disease biomarkers, cellular subsets, therapeutic targets, and diagnostics.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection
Article Hematology

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Kevin R. Kelly et al.

Summary: The study aimed to evaluate the safety and activity of indatuximab ravtansine in combination with immunomodulatory drugs in patients with relapsed or refractory multiple myeloma. The results showed that this combination therapy demonstrated good tolerability and antitumor activity in the patient population.

LANCET HAEMATOLOGY (2021)

Add to Collection
Article Hematology

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

Mehdi Hamadani et al.

Lancet Haematology (2021)

Add to Collection
Article Oncology

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report

Rebecca Baur et al.

Summary: CAR-T cell therapy shows promise in treating relapsed or refractory lymphoma and leukemia, but can lead to hematotoxicity, including anemia and thrombocytopenia, which may increase the risk of infection or bleeding. Additional supportive measures such as Romiplostim may be used to manage these toxicities, but further clinical studies are needed to confirm the efficacy of this approach.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Review Immunology

Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions

Ban Qi Tay et al.

Summary: Advances in genetics, molecular biology, biochemistry, and immunology have led to promising developments in cancer vaccine research, with novel delivery methods and combination therapies offering new hope for the future of cancer vaccines.

VACCINES (2021)

Add to Collection
Review Medicine, General & Internal

Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma A Systematic Review and Meta-analysis

Jun Du et al.

Summary: This study compared the efficacy and safety of allogeneic HSCT and autologous HSCT in treating refractory or relapsed peripheral T-cell lymphoma, and found that both had similar overall survival and progression-free survival outcomes, with allogeneic HSCT potentially offering specific survival benefits in certain patient populations.

JAMA NETWORK OPEN (2021)

Add to Collection
Review Oncology

Cellular immunotherapy for hematological malignancy: recent progress and future perspectives

Zhengli Xu et al.

Summary: Advancements in cellular immunotherapy have revolutionized the treatment of hematologic malignancies by utilizing the patient's immune system to target cancer cells. While CAR-T cell therapy has shown success in treating certain malignancies, challenges such as resistance and non-durable efficacy remain. Strategies like NK cell therapy and haploidentical allografts are being explored as complementary treatments to achieve curative effects, especially in refractory cases.

CANCER BIOLOGY & MEDICINE (2021)

Add to Collection
Review Oncology

Therapeutic cancer vaccines

Mansi Saxena et al.

Summary: Therapeutic cancer vaccines aim to induce tumor regression, eradicate minimal residual disease, establish lasting anti-tumor memory, and avoid non-specific or adverse reactions. However, challenges arise due to tumor-induced immunosuppression and immunoresistance, hindering the achievement of these goals.

NATURE REVIEWS CANCER (2021)

Add to Collection
Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with distinct phenotypes of thyroid irAEs showing unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer survival outcomes, while no association was found between hypothyroidism and cancer outcomes.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection
Article Dermatology

Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis

Amrita Goyal et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection
Review Biotechnology & Applied Microbiology

Translating gammadelta (gamma delta) T cells and their receptors into cancer cell therapies

Zsolt Sebestyen et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Add to Collection
Review Oncology

CAR-NK for tumor immunotherapy: Clinical transformation and future prospects

Wenxiu Wang et al.

CANCER LETTERS (2020)

Add to Collection
Review Pharmacology & Pharmacy

CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress

Sarah A. Holstein et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection
Article Oncology

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Article Hematology

Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study

Sandra Cohen et al.

LANCET HAEMATOLOGY (2020)

Add to Collection
Article Hematology

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Elise Fournier et al.

BLOOD (2020)

Add to Collection
Article Hematology

Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia

Xin He et al.

BLOOD (2020)

Add to Collection
Review Oncology

A review of cancer immunotherapy toxicity

Lucy Boyce Kennedy et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Add to Collection
Review Urology & Nephrology

Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation

Amanda DeMauro Renaghan et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

Add to Collection
Article Oncology

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

Richard F. Schlenk et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Article Oncology

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

Max S. Topp et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Article Cardiac & Cardiovascular Systems

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis

Magid Awadalla et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection
Article Oncology

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial et al.

LANCET ONCOLOGY (2020)

Add to Collection
Article Oncology

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm

Elodie Bole-Richard et al.

LEUKEMIA (2020)

Add to Collection
Article Oncology

Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)

George R. Nahas et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection
Article Biotechnology & Applied Microbiology

An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity

Yik Andy Yeung et al.

MOLECULAR THERAPY (2020)

Add to Collection
Review Biotechnology & Applied Microbiology

'Off-the-shelf' allogeneic CAR T cells: development and challenges

S. Depil et al.

NATURE REVIEWS DRUG DISCOVERY (2020)

Add to Collection
Article Medicine, General & Internal

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection
Article Immunology

Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant

David M. Burns et al.

TRANSPLANTATION (2020)

Add to Collection
Article Immunology

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity

Laura Strauss et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection
Article Cell Biology

Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics

Felix Horns et al.

CELL REPORTS (2020)

Add to Collection
Review Immunology

Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics

Heliang Li et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Add to Collection
Review Biochemistry & Molecular Biology

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside

Antonio G. Solimando et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection
Review Hematology

Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement

Kris M. Mahadeo et al.

LANCET HAEMATOLOGY (2020)

Add to Collection
Article Hematology

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

Olaf Penack et al.

Lancet Haematology (2020)

Add to Collection
Article Oncology

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

Sham Mailankody et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Article Oncology

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study

Houli Zhao et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Article Cell Biology

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Maud Mayoux et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection
Article Multidisciplinary Sciences

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer

Ge Qin et al.

NATURE COMMUNICATIONS (2020)

Add to Collection
Review Dermatology

Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features

Samantha R. Ellis et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection
Review Dermatology

Immune checkpoint inhibitor-related dermatologic adverse events

Amaris N. Geisler et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection
Review Immunology

Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)

Robert David Sandler et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Review Immunology

Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation

Francesca Bonifazi et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Review Oncology

T cell-engaging therapies - BiTEs and beyond

Maria-Elisabeth Goebeler et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Add to Collection
Article Medicine, General & Internal

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection
Article Oncology

Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis

Virginie Grouthier et al.

ONCOLOGIST (2020)

Add to Collection
Article Oncology

Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study

Feng-Mei Zheng et al.

CANCER COMMUNICATIONS (2020)

Add to Collection
Article Allergy

Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies

Craig W. Freyer et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection
Article Oncology

Chronic immune checkpoint inhibitor pneumonitis

Jarushka Naidoo et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Article Oncology

Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes

Alejandro Meraz-Munoz et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Review Oncology

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

John Haanen et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Article Oncology

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Carlos A. Ramos et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection
Article Immunology

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial

Matthew J. Frank et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Add to Collection
Article Hematology

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Tania Jain et al.

BLOOD ADVANCES (2020)

Add to Collection
Review Urology & Nephrology

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events

Sandra M. Herrmann et al.

KIDNEY INTERNATIONAL REPORTS (2020)

Add to Collection
Article Hematology

Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status

Yue Lu et al.

ANNALS OF HEMATOLOGY (2020)

Add to Collection
Article Oncology

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles et al.

LANCET ONCOLOGY (2020)

Add to Collection
Article Oncology

Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Luke Coyle et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection
Article Oncology

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

Runxia Gu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Qing Deng et al.

NATURE MEDICINE (2020)

Add to Collection
Article Biochemistry & Molecular Biology

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nirav N. Shah et al.

NATURE MEDICINE (2020)

Add to Collection
Article Medicine, General & Internal

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

Robin Foa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection
Article Hematology

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Catherine S Diefenbach et al.

Lancet Haematology (2020)

Add to Collection
Review Multidisciplinary Sciences

Revisiting the PD-1 pathway

Nikolaos Patsoukis et al.

SCIENCE ADVANCES (2020)

Add to Collection
Article Oncology

Point mutation inCD19facilitates immune escape of B cell lymphoma from CAR-T cell therapy

Zhen Zhang et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection
Review Medicine, General & Internal

CAR-NK cells: A promising cellular immunotherapy for cancer

Guozhu Xie et al.

EBIOMEDICINE (2020)

Add to Collection
Review Biochemistry & Molecular Biology

Immunotherapy for advanced hepatocellular carcinoma, where are we?

Li Zhang et al.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)

Add to Collection
Review Oncology

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Ahmet Yilmaz et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection
Article Multidisciplinary Sciences

Anti-tumour immunity induces aberrant peptide presentation in melanoma

Osnat Bartok et al.

NATURE (2020)

Add to Collection
Article Multidisciplinary Sciences

Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

Sri Krishna et al.

SCIENCE (2020)

Add to Collection
Article Immunology

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Xuan Zhou et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Meeting Abstract Hematology

Long-Term Safety Profile of the Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib in Immune Thrombocytopenia (ITP) and Other Diseases

Sandra Tong et al.

BLOOD (2020)

Add to Collection
Meeting Abstract Hematology

A Phase I/IIa Study of Lemzoparlimab, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Initial Phase I Results

Junyuan Qi et al.

BLOOD (2020)

Add to Collection
Meeting Abstract Hematology

A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)

Carlos Bachier et al.

BLOOD (2020)

Add to Collection
Meeting Abstract Hematology

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Simon J. Harrison et al.

BLOOD (2020)

Add to Collection
Meeting Abstract Hematology

Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma

Shaji K. Kumar et al.

BLOOD (2020)

Add to Collection
Meeting Abstract Hematology

Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Alexander M. Lesokhin et al.

BLOOD (2020)

Add to Collection
Article Immunology

A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma

Xinfeng Chen et al.

IMMUNOTHERAPY (2020)

Add to Collection
Article Biochemistry & Molecular Biology

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma

Jianshu Wei et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection
Article Oncology

Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells

Roberta Sommaggio et al.

ONCOIMMUNOLOGY (2020)

Add to Collection
Article Oncology

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma

Sikander Ailawadhi et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)

Add to Collection
Article Biophysics

Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome

Marte B. Kammersgaard et al.

BONE MARROW TRANSPLANTATION (2019)

Add to Collection
Article Biophysics

Early and late hematologic toxicity following CD19 CAR-T cells

Shalev Fried et al.

BONE MARROW TRANSPLANTATION (2019)

Add to Collection
Article Oncology

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Laura Moreno et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection
Article Oncology

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release

Christina L. Zuch de Zafra et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection
Review Endocrinology & Metabolism

A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors

Jeroen de Filette et al.

HORMONE AND METABOLIC RESEARCH (2019)

Add to Collection
Article Hematology

A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma

Ken Ohmachi et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)

Add to Collection
Article Oncology

Management of Immunotherapy-Related Toxicities. Version 1.2019

John A. Thompson et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)

Add to Collection
Article Multidisciplinary Sciences

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

Mohamad Hamieh et al.

NATURE (2019)

Add to Collection
Article Cell Biology

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Eric L. Smith et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Add to Collection
Article Hematology

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Franck Morschhauser et al.

LANCET HAEMATOLOGY (2019)

Add to Collection
Article Immunology

Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity

Marine Cazaux et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2019)

Add to Collection
Article Oncology

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study

Herve Tilly et al.

LANCET ONCOLOGY (2019)

Add to Collection
Article Medicine, General & Internal

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection
Article Oncology

Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts

Luke Jones et al.

PEDIATRIC BLOOD & CANCER (2019)

Add to Collection
Review Pharmacology & Pharmacy

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

Frans V. Suurs et al.

PHARMACOLOGY & THERAPEUTICS (2019)

Add to Collection
Article Multidisciplinary Sciences

leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

Jie Xu et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Add to Collection
Review Cell Biology

Phage display screening of therapeutic peptide for cancer targeting and therapy

Phei Er Saw et al.

PROTEIN & CELL (2019)

Add to Collection
Review Endocrinology & Metabolism

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review

Jeroen M. K. de Filette et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)

Add to Collection
Article Biotechnology & Applied Microbiology

MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis

Pieter Fokko van Loo et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2019)

Add to Collection
Article Immunology

Complications of Stem Cell Transplantation that Affect Infections in Stem Cell Transplant Recipients, with Analogies to Patients with Hematologic Malignancies

Sunita Nathan et al.

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)

Add to Collection
Article Immunology

Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient

Elizabeth Ann Misch et al.

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)

Add to Collection
Article Immunology

Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient

Lauren Fontana et al.

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)

Add to Collection
Article Oncology

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Gregory S. Phillips et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection
Article Oncology

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11

Johannes Duell et al.

JOURNAL OF IMMUNOTHERAPY (2019)

Add to Collection
Article Immunology

PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

Vivek Verma et al.

NATURE IMMUNOLOGY (2019)

Add to Collection
Article Hematology

Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial

Huiwen Jiang et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection
Article Oncology

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study

Pier Luigi Zinzani et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection
Article Chemistry, Medicinal

Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)

Ute F. Rohrig et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

Add to Collection
Article Oncology

Management of cytokine release syndrome related to CAR-T cell therapy

Hongli Chen et al.

FRONTIERS OF MEDICINE (2019)

Add to Collection
Meeting Abstract Hematology

Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)

Caitlin L. Costello et al.

BLOOD (2019)

Add to Collection
Review Oncology

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy

Xiao Han et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection
Article Hematology

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

Zhiling Yan et al.

LANCET HAEMATOLOGY (2019)

Add to Collection
Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection
Review Hematology

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

Jennifer N. Brudno et al.

BLOOD REVIEWS (2019)

Add to Collection
Review Respiratory System

Management of pulmonary toxicity associated with immune checkpoint inhibitors

Myriam Delaunay et al.

EUROPEAN RESPIRATORY REVIEW (2019)

Add to Collection
Review Hematology

Diagnosis of Hodgkin lymphoma in the modern era

Hao-Wei Wang et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Add to Collection
Review Public, Environmental & Occupational Health

Safety and Tolerability of Antibody-Drug Conjugates in Cancer

Anna Wolska-Washer et al.

DRUG SAFETY (2019)

Add to Collection
Article Oncology

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Stephen M. Ansell et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection
Article Medicine, General & Internal

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven Horwitz et al.

LANCET (2019)

Add to Collection
Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

Add to Collection
Article Oncology

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

Filipe Martins et al.

LANCET ONCOLOGY (2019)

Add to Collection
Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection
Article Medicine, General & Internal

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal et al.

LANCET (2019)

Add to Collection
Article Oncology

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Susanne H. Baumeister et al.

CANCER IMMUNOLOGY RESEARCH (2019)

Add to Collection
Article Hematology

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Anas Younes et al.

LANCET HAEMATOLOGY (2019)

Add to Collection
Article Oncology

Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients

Andre Tichelli et al.

JAMA ONCOLOGY (2019)

Add to Collection
Article Hematology

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

Rebecca Karp Leaf et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection
Review Chemistry, Multidisciplinary

Cleavable linkers in antibody-drug conjugates

Jonathan D. Bargh et al.

CHEMICAL SOCIETY REVIEWS (2019)

Add to Collection
Review Oncology

Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?

Xiao-Su Zhao et al.

BIOMARKER RESEARCH (2019)

Add to Collection
Article Biochemistry & Molecular Biology

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Terry J. Fry et al.

NATURE MEDICINE (2018)

Add to Collection
Review Oncology

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities

Sattva S. Neelapu et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection
Letter Oncology

Hypogammaglobulinemia due to CAR T-cell therapy

Michael A. Pulsipher

PEDIATRIC BLOOD & CANCER (2018)

Add to Collection
Review Cell Biology

T-cell receptor-engineered T cells for cancer treatment: current status and future directions

Yu Ping et al.

PROTEIN & CELL (2018)

Add to Collection
Correction Oncology

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness (vol 23, pg 2356, 2012)

M. S. Czuczman et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection
Article Oncology

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

W. Jurczak et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection
Correction Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)

J. B. A. G. Haanen et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection
Article Hematology

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

Frank Vari et al.

BLOOD (2018)

Add to Collection
Review Oncology

Bispecific antibodies in haematological malignancies

Andreas Viardot et al.

CANCER TREATMENT REVIEWS (2018)

Add to Collection
Article Oncology

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

Olivia Campagne et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection
Article Oncology

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study

Anastasios Stathis et al.

INVESTIGATIONAL NEW DRUGS (2018)

Add to Collection
Article Oncology

Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.

Joshua Ryan Richter et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Article Oncology

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection
Article Oncology

CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia

Jinghua Wang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

Add to Collection
Article Gastroenterology & Hepatology

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

Eleonora De Martin et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection
Article Oncology

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

John A. Thompson

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)

Add to Collection
Article Oncology

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

Hagop Kantarjian et al.

LANCET ONCOLOGY (2018)

Add to Collection
Article Oncology

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation

Colin E. Correnti et al.

LEUKEMIA (2018)

Add to Collection
Article Pathology

Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury

Yoh Zen et al.

MODERN PATHOLOGY (2018)

Add to Collection
Article Oncology

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML

Yelena Kovtun et al.

MOLECULAR CANCER THERAPEUTICS (2018)

Add to Collection
Article Biochemistry & Molecular Biology

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Margherita Norelli et al.

NATURE MEDICINE (2018)

Add to Collection
Article Biochemistry & Molecular Biology

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Theodoros Giavridis et al.

NATURE MEDICINE (2018)

Add to Collection
Article Biochemistry & Molecular Biology

A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects

Yuki Kagoya et al.

NATURE MEDICINE (2018)

Add to Collection
Editorial Material Biochemical Research Methods

Exponential scaling of single-cell RNA-seq in the past decade

Valentine Svensson et al.

NATURE PROTOCOLS (2018)

Add to Collection
Review Biotechnology & Applied Microbiology

The promise and challenges of immune agonist antibody development in cancer

Patrick A. Mayes et al.

NATURE REVIEWS DRUG DISCOVERY (2018)

Add to Collection
Review Gastroenterology & Hepatology

Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management

Mark A. Samaan et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)

Add to Collection
Article Medicine, General & Internal

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

J. F. Seymour et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Article Medicine, General & Internal

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

M. -V. Mateos et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Article Medicine, General & Internal

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

J. M. Connors et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Article Oncology

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Robert Q. Le et al.

ONCOLOGIST (2018)

Add to Collection
Article Oncology

Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade

Kerry Reynolds et al.

ONCOLOGIST (2018)

Add to Collection
Article Oncology

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Bianca D. Santomasso et al.

CANCER DISCOVERY (2018)

Add to Collection
Article Oncology

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates

Agne Taraseviciute et al.

CANCER DISCOVERY (2018)

Add to Collection
Article Oncology

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Limo Chen et al.

CANCER DISCOVERY (2018)

Add to Collection
Article Oncology

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma

Wing Keung Chan et al.

CANCER IMMUNOLOGY RESEARCH (2018)

Add to Collection
Article Oncology

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial

Elias Jabbour et al.

JAMA ONCOLOGY (2018)

Add to Collection
Article Hematology

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

Amir T. Fathi et al.

BLOOD (2018)

Add to Collection
Article Biochemistry & Molecular Biology

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Marco Ruella et al.

NATURE MEDICINE (2018)

Add to Collection
Review Oncology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Spencer C. Wei et al.

CANCER DISCOVERY (2018)

Add to Collection
Article

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

Noelle Frey et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)

Add to Collection
Article Hematology

Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia

Monika Herrmann et al.

BLOOD (2018)

Add to Collection
Article Clinical Neurology

Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies

Juliane Gust et al.

CNS DRUGS (2018)

Add to Collection
Article Immunology

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Christopher S. Garris et al.

IMMUNITY (2018)

Add to Collection
Article Oncology

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Wan-Hong Zhao et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

Add to Collection
Article Oncology

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

Suzanne Trudel et al.

LANCET ONCOLOGY (2018)

Add to Collection
Article Multidisciplinary Sciences

Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome

Verena Staedtke et al.

NATURE (2018)

Add to Collection
Article Medicine, General & Internal

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma

Ranjana Advani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Review Immunology

Improving Immunotherapy Through Glycodesign

Matthew J. Buettner et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection
Review Oncology

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Michael M. Boyiadzis et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection
Article Oncology

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

Karen Thudium Mueller et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection
Review Oncology

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management

Marnix H. Geukes Foppen et al.

ESMO OPEN (2018)

Add to Collection
Meeting Abstract Hematology

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi et al.

BLOOD (2018)

Add to Collection
Meeting Abstract Hematology

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Thorsten Ross et al.

BLOOD (2018)

Add to Collection
Meeting Abstract Hematology

Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jorge E. Cortes et al.

BLOOD (2018)

Add to Collection
Review Immunology

Towards personalized, tumour-specific, therapeutic vaccines for cancer

Zhuting Hu et al.

NATURE REVIEWS IMMUNOLOGY (2018)

Add to Collection
Letter Hematology

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia

Nicholas J. Short et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Add to Collection
Article Hematology

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

Elias Jabbour et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Add to Collection
Article Hematology

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia

Peter G. Maslak et al.

BLOOD ADVANCES (2018)

Add to Collection
Article Hematology

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy

Joshua A. Hill et al.

BLOOD (2018)

Add to Collection
Review Hematology

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

Zijun Y. Xu-Monette et al.

BLOOD (2018)

Add to Collection
Review Hematology

Redirecting T cells to hematological malignancies with bispecific antibodies

Mireya Paulina Velasquez et al.

BLOOD (2018)

Add to Collection
Article Hematology

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

Eytan M. Stein et al.

BLOOD (2018)

Add to Collection
Article Hematology

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Friederike Braig et al.

BLOOD (2017)

Add to Collection
Article Oncology

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

Chun-Meng Wang et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection
Review Urology & Nephrology

Renal dysfunction following bone marrow transplantation

Stephan Kemmner et al.

JOURNAL OF NEPHROLOGY (2017)

Add to Collection
Editorial Material Hematology

Better acute graft-versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?

Mahasweta Gooptu et al.

HAEMATOLOGICA (2017)

Add to Collection
Article Hematology

Improved survival after acute graft-versus-host disease diagnosis in the modern era

Hanna J. Khoury et al.

HAEMATOLOGICA (2017)

Add to Collection
Article Medicine, Research & Experimental

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes

Carlos A. Ramos et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

Add to Collection
Article Oncology

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy

Jarushka Naidoo et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection
Review Oncology

Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome

James A. Kennedy et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection
Article Oncology

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection
Article Immunology

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

Vikram R. Juneja et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2017)

Add to Collection
Review Oncology

Immunotherapy in hematologic malignancies: past, present, and future

Annie Im et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

Add to Collection
Article Medicine, General & Internal

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince et al.

LANCET (2017)

Add to Collection
Review Medicine, General & Internal

Non-Hodgkin lymphoma

James O. Armitage et al.

LANCET (2017)

Add to Collection
Article Biotechnology & Applied Microbiology

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Frederick L. Locke et al.

MOLECULAR THERAPY (2017)

Add to Collection
Article Multidisciplinary Sciences

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

Sydney R. Gordon et al.

NATURE (2017)

Add to Collection
Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection
Article Medicine, General & Internal

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection
Review Multidisciplinary Sciences

Single-cell transcriptomics to explore the immune system in health and disease

Michael J. T. Stubbington et al.

SCIENCE (2017)

Add to Collection
Article Oncology

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Juliane Gust et al.

CANCER DISCOVERY (2017)

Add to Collection
Editorial Material Hematology

Better acute graft-versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?

Mahasweta Gooptu et al.

HAEMATOLOGICA (2017)

Add to Collection
Article Hematology

Improved survival after acute graft-versus-host disease diagnosis in the modern era

Hanna J. Khoury et al.

HAEMATOLOGICA (2017)

Add to Collection
Review Pharmacology & Pharmacy

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

Vivek Kumar et al.

FRONTIERS IN PHARMACOLOGY (2017)

Add to Collection
Article Oncology

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

I. Puzanov et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

Add to Collection
Article Hematology

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma

Reid W. Merryman et al.

BLOOD ADVANCES (2017)

Add to Collection
Article Oncology

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies

M. Collins et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection
Review Medicine, Research & Experimental

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Gilles Salles et al.

ADVANCES IN THERAPY (2017)

Add to Collection
Article Biochemistry & Molecular Biology

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Spencer C. Wei et al.

CELL (2017)

Add to Collection
Article Pharmacology & Pharmacy

Inotuzumab Ozogamicin: First Global Approval

Yvette N. Lamb

DRUGS (2017)

Add to Collection
Article Hematology

Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia

Ibrahim Aldoss et al.

AMERICAN JOURNAL OF HEMATOLOGY (2017)

Add to Collection
Article Hematology

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Pier Luigi Zinzani et al.

BLOOD (2017)

Add to Collection
Article Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J. B. A. G. Haanen et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection
Article Hematology

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Wei Ding et al.

BLOOD (2017)

Add to Collection
Article Hematology

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

Lakshmi Nayak et al.

BLOOD (2017)

Add to Collection
Article Pharmacology & Pharmacy

Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies

Kevin A. Hay et al.

DRUGS (2017)

Add to Collection
Review Hematology

Hematopoietic stem cell transplantation for patients with AML in first complete remission

Jan J. Cornelissen et al.

BLOOD (2016)

Add to Collection
Review Oncology

Modern approaches to HLA-haploidentical blood or marrow transplantation

Christopher G. Kanakry et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

Add to Collection
Article Hematology

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

A. Viardot et al.

BLOOD (2016)

Add to Collection
Letter Hematology

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

Guillaume Olombel et al.

BLOOD (2016)

Add to Collection
Article Hematology

Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL

Xiuli Wang et al.

BLOOD (2016)

Add to Collection
Article Hematology

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik et al.

BLOOD (2016)

Add to Collection
Article Oncology

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Uwe Reusch et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection
Article Oncology

Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study

Yu Wang et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection
Article Pharmacology & Pharmacy

Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique

Xenia A. Glukhova et al.

CURRENT PHARMACEUTICAL DESIGN (2016)

Add to Collection
Article Oncology

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

V. R. Belum et al.

EUROPEAN JOURNAL OF CANCER (2016)

Add to Collection
Article Medicine, Research & Experimental

CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients

Cameron J. Turtle et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

Add to Collection
Article Oncology

Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation

Ying-Jun Chang et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection
Article Oncology

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Philippe Armand et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection
Article Oncology

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

Margaretha G. M. Roemer et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection
Article Oncology

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

Maria-Elisabeth Goebeler et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection
Article Medicine, General & Internal

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial et al.

LANCET (2016)

Add to Collection
Review Oncology

Antibody-drug conjugates for cancer therapy

Anish Thomas et al.

LANCET ONCOLOGY (2016)

Add to Collection
Article Oncology

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Laurie H. Sehn et al.

LANCET ONCOLOGY (2016)

Add to Collection
Article Oncology

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes et al.

LANCET ONCOLOGY (2016)

Add to Collection
Letter Medicine, General & Internal

Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Jinichi Mori et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection
Article Medicine, General & Internal

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

M. A. Dimopoulos et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection
Article Medicine, General & Internal

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection
Article Medicine, General & Internal

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Hagop M. Kantarjian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection
Article Oncology

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges

Emilie M. J. van Brummelen et al.

ONCOLOGIST (2016)

Add to Collection
Article Oncology

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

David T. Teachey et al.

CANCER DISCOVERY (2016)

Add to Collection
Review Oncology

Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis

Mizuki Nishino et al.

JAMA ONCOLOGY (2016)

Add to Collection
Meeting Abstract Hematology

CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics

Martin Felices et al.

BLOOD (2016)

Add to Collection
Article Oncology

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro

H. Tilly et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection
Article Hematology

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

Stefan O. Ciurea et al.

BLOOD (2015)

Add to Collection
Article Hematology

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study

Yu Wang et al.

BLOOD (2015)

Add to Collection
Letter Hematology

Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo

Thomas R. W. Tipton et al.

BLOOD (2015)

Add to Collection
Review Hematology

Immune checkpoint blockade in hematologic malignancies

Philippe Armand

BLOOD (2015)

Add to Collection
Review Hematology

How I treat hemophagocytic lymphohistiocytosis in the adult patient

Alison M. Schram et al.

BLOOD (2015)

Add to Collection
Review Immunology

Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

Omar Abdel-Rahman et al.

IMMUNOTHERAPY (2015)

Add to Collection
Review Oncology

Immune Checkpoint Blockade in Cancer Therapy

Michael A. Postow et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection
Article Oncology

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment

Frauke M. Schnorfeil et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)

Add to Collection
Article Medicine, General & Internal

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Peter Hillmen et al.

LANCET (2015)

Add to Collection
Article Oncology

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Max S. Topp et al.

LANCET ONCOLOGY (2015)

Add to Collection
Article Oncology

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial

Luis Fayad et al.

LEUKEMIA & LYMPHOMA (2015)

Add to Collection
Article Medicine, Research & Experimental

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells

Uwe Reusch et al.

MABS (2015)

Add to Collection
Article Medicine, Research & Experimental

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Marije B. Overdijk et al.

MABS (2015)

Add to Collection
Review Medicine, General & Internal

Hodgkin Lymphoma: Diagnosis and Treatment

Stephen M. Ansell

MAYO CLINIC PROCEEDINGS (2015)

Add to Collection
Article Oncology

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

Daniel S. Pereira et al.

MOLECULAR CANCER THERAPEUTICS (2015)

Add to Collection
Article Biotechnology & Applied Microbiology

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

Tao Dao et al.

NATURE BIOTECHNOLOGY (2015)

Add to Collection
Article Oncology

Erratum: Modern approaches to HLA-haploidentical blood or marrow transplantation.

Christopher G. Kanakry et al.

Nature Reviews Clinical Oncology (2015)

Add to Collection
Review Biotechnology & Applied Microbiology

Combination cancer immunotherapy and new immunomodulatory targets

Kathleen M. Mahoney et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Add to Collection
Review Biotechnology & Applied Microbiology

The pharmacology of second-generation chimeric antigen receptors

Sjoukje J. C. van der Stegen et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Add to Collection
Review Medicine, General & Internal

Acute Myeloid Leukemia

Hartmut Doehner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection
Article Medicine, General & Internal

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Sagar Lonial et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection
Article Medicine, General & Internal

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

H. M. Lokhorst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection
Article Medicine, General & Internal

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection
Article Multidisciplinary Sciences

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

Emanuela Romano et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)

Add to Collection
Article Cell Biology

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies

Liping L. Sun et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

Add to Collection
Review Oncology

Immune evasion in cancer: Mechanistic basis and therapeutic strategies

Dass S. Vinay et al.

SEMINARS IN CANCER BIOLOGY (2015)

Add to Collection
Article Oncology

Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy

A. S. Nelson et al.

LEUKEMIA (2015)

Add to Collection
Article Oncology

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

Kristen N. Ganjoo et al.

LEUKEMIA & LYMPHOMA (2015)

Add to Collection
Review Oncology

Haematological malignancies: at the forefront of immunotherapeutic innovation

Pavan Bachireddy et al.

NATURE REVIEWS CANCER (2015)

Add to Collection
Review Chemistry, Multidisciplinary

Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy

Ravi V. J. Chari et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)

Add to Collection
Article Hematology

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

Xiaoou Zhou et al.

BLOOD (2014)

Add to Collection
Review Hematology

The biology of graft-versus-host disease: experimental systems instructing clinical practice

Kate A. Markey et al.

BLOOD (2014)

Add to Collection
Article Hematology

HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse

Massimo F. Martelli et al.

BLOOD (2014)

Add to Collection
Review Hematology

Current concepts in the diagnosis and management of cytokine release syndrome

Daniel W. Lee et al.

BLOOD (2014)

Add to Collection
Letter Hematology

Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line

Mitchell R. Smith et al.

BRITISH JOURNAL OF HAEMATOLOGY (2014)

Add to Collection
Meeting Abstract Oncology

Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia

Daniel S. Pereira et al.

CANCER RESEARCH (2014)

Add to Collection
Article Oncology

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Vincent Ribrag et al.

CLINICAL CANCER RESEARCH (2014)

Add to Collection
Article Oncology

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

Alan S. Gamis et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection
Article Oncology

Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Max S. Topp et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection
Article Oncology

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Jason R. Westin et al.

LANCET ONCOLOGY (2014)

Add to Collection
Article Medicine, Research & Experimental

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

Uwe Reusch et al.

MABS (2014)

Add to Collection
Article Medicine, Research & Experimental

Ocaratuzumab, an Fc- engineered antibody demonstrates enhanced antibody- dependent cell- mediated cytotoxicity in chronic lymphocytic leukemia

Carolyn M. Cheney et al.

MABS (2014)

Add to Collection
Article Medicine, General & Internal

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Shannon L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection
Article Medicine, General & Internal

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection
Review Oncology

The tumour microenvironment in B cell lymphomas

David W. Scott et al.

NATURE REVIEWS CANCER (2014)

Add to Collection
Review Medicine, General & Internal

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults

Udo Holtick et al.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)

Add to Collection
Article Hematology

Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia

Andrea Pession et al.

BLOOD (2013)

Add to Collection
Article Hematology

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)

John Radford et al.

BLOOD (2013)

Add to Collection
Article Hematology

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

Conrad Russell Y. Cruz et al.

BLOOD (2013)

Add to Collection
Article Hematology

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf et al.

BLOOD (2013)

Add to Collection
Article Hematology

BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation

Fiona L. Dignan et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

Add to Collection
Article Oncology

The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia

Hernan Carol et al.

CLINICAL CANCER RESEARCH (2013)

Add to Collection
Review Immunology

Deciphering and Reversing Tumor Immune Suppression

Greg T. Motz et al.

IMMUNITY (2013)

Add to Collection
Review Immunology

Oncology Meets Immunology: The Cancer-Immunity Cycle

Daniel S. Chen et al.

IMMUNITY (2013)

Add to Collection
Article Oncology

Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group

Cornelia Eckert et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection
Article Oncology

Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study

Gilles A. Salles et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection
Article Oncology

90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial

Franck Morschhauser et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection
Article Oncology

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

Philippe Armand et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection
Article Oncology

Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)

Sergio Amadori et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection
Article Oncology

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

Franck Andre Morschhauser et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection
Article Oncology

Milatuzumab-SN-38 Conjugates for the Treatment of CD74 Cancers

Serengulam V. Govindan et al.

MOLECULAR CANCER THERAPEUTICS (2013)

Add to Collection
Article Oncology

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Sylvia Herter et al.

MOLECULAR CANCER THERAPEUTICS (2013)

Add to Collection
Article Oncology

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

M. Aigner et al.

LEUKEMIA (2013)

Add to Collection
Article Medicine, General & Internal

Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia

Stephan A. Grupp et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection
Editorial Material Multidisciplinary Sciences

Cancer Immunotherapy

Marcia McNutt

SCIENCE (2013)

Add to Collection
News Item Multidisciplinary Sciences

Cancer Immunotherapy

Jennifer Couzin-Frankel

SCIENCE (2013)

Add to Collection
Article Oncology

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

Marcela V. Maus et al.

CANCER IMMUNOLOGY RESEARCH (2013)

Add to Collection
Review Oncology

Adverse events to monoclonal antibodies used for cancer therapy Focus on hypersensitivity responses

Brian A. Baldo

ONCOIMMUNOLOGY (2013)

Add to Collection
Article Hematology

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Gilles Salles et al.

BLOOD (2012)

Add to Collection
Article Hematology

Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004

Henrik Hasle et al.

BLOOD (2012)

Add to Collection
Article Hematology

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger et al.

BLOOD (2012)

Add to Collection
Article Hematology

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

Roland B. Walter et al.

BLOOD (2012)

Add to Collection
Article Oncology

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

Michael R. Green et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection
Article Oncology

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

Andres Forero-Torres et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection
Article Hematology

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Anna Sureda et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)

Add to Collection
Article Oncology

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

Robert J. Kreitman et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection
Article Oncology

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Barbara Pro et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection
Article Oncology

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

Alan K. Burnett et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection
Article Oncology

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection
Article Medicine, General & Internal

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Sylvie Castaigne et al.

LANCET (2012)

Add to Collection
Article Oncology

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

Ralf Trappe et al.

LANCET ONCOLOGY (2012)

Add to Collection
Article Oncology

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop Kantarjian et al.

LANCET ONCOLOGY (2012)

Add to Collection
Review Pharmacology & Pharmacy

Blinatumomab: A historical perspective

Dirk Nagorsen et al.

PHARMACOLOGY & THERAPEUTICS (2012)

Add to Collection
Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

Add to Collection
Article Hematology

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

Cor H. J. Lamers et al.

BLOOD (2011)

Add to Collection
Article Hematology

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma

Lapo Alinari et al.

BLOOD (2011)

Add to Collection
Article Hematology

A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia

John Schindler et al.

BRITISH JOURNAL OF HAEMATOLOGY (2011)

Add to Collection
Review Oncology

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

Dirk Nagorsen et al.

EXPERIMENTAL CELL RESEARCH (2011)

Add to Collection
Review Immunology

Hybridoma technologies for antibody production

Masahiro Tomita et al.

IMMUNOTHERAPY (2011)

Add to Collection
Article Oncology

Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection
Article Medicine, General & Internal

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles et al.

LANCET (2011)

Add to Collection
Review Immunology

Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation

Kajsa Wing et al.

TRENDS IN IMMUNOLOGY (2011)

Add to Collection
Review Immunology

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

Lucy S. K. Walker et al.

NATURE REVIEWS IMMUNOLOGY (2011)

Add to Collection
Article Oncology

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

F. Morschhauser et al.

ANNALS OF ONCOLOGY (2010)

Add to Collection
Article Hematology

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CDI9-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

Michael C. Jensen et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)

Add to Collection
Article Hematology

Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells

Erin Hertlein et al.

BLOOD (2010)

Add to Collection
Article Hematology

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

Ekkehard Moessner et al.

BLOOD (2010)

Add to Collection
Article Hematology

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

Michael R. Green et al.

BLOOD (2010)

Add to Collection
Article Hematology

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Bob Lowenberg et al.

BLOOD (2010)

Add to Collection
Article Immunology

Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6

E. LEGOUFFE et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)

Add to Collection
Article Oncology

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

Alan S. Wayne et al.

CLINICAL CANCER RESEARCH (2010)

Add to Collection
Article Hematology

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

Mohamad Hussein et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)

Add to Collection
Article Oncology

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

Anjali Advani et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection
Article Medicine, General & Internal

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

M. Hallek et al.

LANCET (2010)

Add to Collection
Article Biotechnology & Applied Microbiology

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Richard A. Morgan et al.

MOLECULAR THERAPY (2010)

Add to Collection
Review Biotechnology & Applied Microbiology

The safety and side effects of monoclonal antibodies

Trevor T. Hansel et al.

NATURE REVIEWS DRUG DISCOVERY (2010)

Add to Collection
Article Medicine, General & Internal

Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.

Ted A. Gooley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection
Article Multidisciplinary Sciences

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

Viggo F. Van Tendeloo et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

Add to Collection
Article Hematology

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

Asad Bashey et al.

BLOOD (2009)

Add to Collection
Article Hematology

Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation

Corey Smith et al.

BLOOD (2009)

Add to Collection
Article Hematology

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

Ulrich Keilholz et al.

BLOOD (2009)

Add to Collection
Article Hematology

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Mojgan Ahmadzadeh et al.

BLOOD (2009)

Add to Collection
Article Oncology

Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines

Rhona Stein et al.

CLINICAL CANCER RESEARCH (2009)

Add to Collection
Article Oncology

Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Stephen M. Ansell et al.

CLINICAL CANCER RESEARCH (2009)

Add to Collection
Article Oncology

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

Franck Morschhauser et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection
Article Oncology

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

Ranjana Advani et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection
Article Oncology

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

A. Cortelezzi et al.

LEUKEMIA (2009)

Add to Collection
Article Oncology

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma

B. Sirohi et al.

ANNALS OF ONCOLOGY (2008)

Add to Collection
Article Hematology

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

Leo Luznik et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)

Add to Collection
Article Hematology

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

Anton Hagenbeek et al.

BLOOD (2008)

Add to Collection
Article Oncology

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

Raanan Berger et al.

CLINICAL CANCER RESEARCH (2008)

Add to Collection
Article Hematology

Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience

Paolo Anderlini et al.

HAEMATOLOGICA (2008)

Add to Collection
Article Allergy

Immunoglobulin Replacement Therapy in Children

Maria Garcia-Lloret et al.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2008)

Add to Collection
Article Multidisciplinary Sciences

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Ralf Bargou et al.

SCIENCE (2008)

Add to Collection
Article Hematology

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Bertrand Coiffier et al.

BLOOD (2008)

Add to Collection
Article Multidisciplinary Sciences

Adaptive immunity maintains occult cancer in an equilibrium state

Catherine M. Koebel et al.

NATURE (2007)

Add to Collection
Review Immunology

Cancer despite immunosurveillance: immunoselection and immunosubversion

Laurence Zitvogel et al.

NATURE REVIEWS IMMUNOLOGY (2006)

Add to Collection
Article Biochemical Research Methods

Isolating and engineering human antibodies using yeast surface display

Ginger Chao et al.

NATURE PROTOCOLS (2006)

Add to Collection
Article Biochemistry & Molecular Biology

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma

SS Neelapu et al.

NATURE MEDICINE (2005)

Add to Collection
Article Oncology

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma

JP Leonard et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection
Article Oncology

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

EJ Feldman et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection
Article Oncology

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)

G Lenz et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection
Review Oncology

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

DJ Hicklin et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection
Article Multidisciplinary Sciences

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

Y Oka et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)

Add to Collection
Review Immunology

The immunobiology of cancer immunosurveillance and immunoediting

GP Dunn et al.

IMMUNITY (2004)

Add to Collection
Article Biochemistry & Molecular Biology

T-cell activation by recombinant immunoreceptors:: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells

C Heuser et al.

GENE THERAPY (2003)

Add to Collection
Article Hematology

Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

Y Oka et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)

Add to Collection
Article Hematology

Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)

N Mounier et al.

BLOOD (2003)

Add to Collection
Article Oncology

Autologous transplantation for aggressive non-hodgkin's lymphoma: Results of a randomized trial evaluating graft source and minimal residual disease

JM Vose et al.

JOURNAL OF CLINICAL ONCOLOGY (2002)

Add to Collection
Article Oncology

Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens

H Bertz et al.

ANNALS OF ONCOLOGY (2002)

Add to Collection
Article Oncology

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

EL Sievers et al.

JOURNAL OF CLINICAL ONCOLOGY (2001)

Add to Collection
Article Oncology

Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

JM Vose et al.

JOURNAL OF CLINICAL ONCOLOGY (2001)

Add to Collection
Article Oncology

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

JM Foran et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.